Erythrocyte-Associated Transients in Capillary PO2 in the Rat Spinotrapezius Muscle During Hemodilution with Hespan and a Hemoglobin-Based Oxygen Carrier by Barker, Matthew
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2005
Erythrocyte-Associated Transients in Capillary
PO2 in the Rat Spinotrapezius Muscle During
Hemodilution with Hespan and a Hemoglobin-
Based Oxygen Carrier
Matthew Barker
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1303
ERYTHROCYTE-ASSOCIATED TRANSIENTS IN CAPILLARY POz IN 
THE RAT SPINOTRAPEZIUS MUSCLE DURING HEMODILUTION 
WITH HESPAN AND A HEMOGLOBIN-BASED OXYGEN CARRIER 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at the Medical College of Virginia Campus, Virginia Commonwealth University 
Matthew C. Barker 
B.S., King College, 2002 
Director: 
Roland N. Pittman, Ph.D. 
Professor 
Department of Physiology 
Virginia Commonwealth University 
Richmond, Virginia 
August, 2005 
ACKNOWLEDGEMENTS 
First, I would like to thank Dr. Roland N. Pittman for his incredible patience, 
encouragement, and generosity, all of which are manifest daily in his immeasurable 
teaching and mentoring skills. Through his dedication to his students, laboratory 
collaborators, and work he creates an atmosphere of high morale, motivation, and 
learning. 
Secondly, I would like to thank the members of this laboratory, whose contributions 
made this project possible. Many thanks to Aleksander Golub, for whom this project 
would not be possible without his scientific and technical knowledge. I am very grateful 
for the patience and help of Mike Tevald, John Lowman, and Helena Carvalho, all of 
whom have imparted significant surgical knowledge that allowed me to get to the point 
where I could even take measurements. I give my thanks to Mike and John for their 
willingness to unselfishly extend their time to teach and instruct me on many occasions. 
My thanks also extends toward Kathleen Hall, a person with whom I had many 
entertaining conversations in sharing an office space and for the advice and 
encouragement to complete my project. I would like to thank everyone for making the 
laboratory like a second home in many ways and for treating me like one of their own 
from day one. 
I would also like to thank my graduate committee members, Dr. Ivo Torres Filho and Dr. 
Wayne Barbee, for their time and last minute scheduling changes that have made my 
project completion possible. 
I am grateful to my family for their support, encouragement, and interest in my project. 
Most of all, I would like to thank Sarah, whose unwavering love and support means 
everything to me and has made this all possible. 
TABLE OF CONTENTS 
. . ACKNOWLEDGEMENTS ................................................................................................ ii 
... TABLE OF CONTENTS ................................................................................................... in 
LIST OF TABLES ............................................................................................................. vi 
. . LIST OF FIGURES .......................................................................................................... vii 
LIST OF ABBREVIATIONS ............................................................................................ ix 
ABSTRACT ..................................................................................................................... xiv 
INTRODUCTION .............................................................................................................. 1 
The Blood and Circulation .............................................................................................. 1 
Blood Composition ..................................................................................................... 1 
Red Blood Cells and Hemoglobin ............................................................................... 2 
The Circulation and Oxygen Transport in Blood Vessels ......................................... 3 
Convection and Diffusion ........................................................................................... 4 
Artificial Oxygen Carriers .............................................................................................. 6 
Historical Background ................................................................................................ 6 
Major Approaches to Artzficial Oxygen Carriers ....................................................... 7 
Perfluorocarbons ..................................................................................................... 8 
Hemoglobin-based Oxygen Carriers ....................................................................... 8 
Hemoglobin-based Oxygen Carriers ............................................................................... 9 
Modzfications of the Hemoglobin Molecule ................................................................ 9 
Physiological Effects of HBOCs ............................................................................... 10 
Possible Indications for HBOCs ............................................................................... 12 
Hemodilution ................................................................................................................ 13 
Erythrocyte-associated Transients in PO2 ..................................................................... 14 
Purpose of the Present Study ........................................................................................ 15 
MATERIALS AND METHODS ...................................................................................... 17 
Anesthesia and Animal Preparation .............................................................................. 17 
Tracheal and Vascular Cannulations ............................................................................ 19 
Spinotrapezius Preparation ........................................................................................... 20 
Phosphorescence Intravital Microscope ....................................................................... 20 
................................................................................... Solution and Probe Preparations 24 
Preparation of Albumin-bound Pd-porphyrin Phosphorescent Probe ..................... 24 
'E Properties and Preparation of Oxyglobin .............................................................. 24 
.................................................................................................... Heparin ized Saline 25 
PO2 Measurements ........................................................................................................ 25 
Capillary Selection and Probe Administration ......................................................... 25 
Phosphorescence Quenching Microscopy (PQM) .................................................... 26 
Light Transmission. Phosphorescence Amplitude Measurements. and PO;? ................ 29 
Mean Arterial Pressure ................................................................................................. 30 
............................................................................................... Hemodilution Procedure 31 
Statistics ...................................................................................................................... 33 
RESULTS ......................................................................................................................... 34 
Phosphorescence Amplitude. Light Transmission and PO;? ........................................ 34 
Effects of Hemodilution with Hespan and Oxyglobin on Systemic Variables ............. 38 
Mean Arterial Pressure and Hematocrit .................................................................. 38 
Mean Arterial Pressure and Plasma Hemoglobin .................................................... 41 
Effects of Hemodilution with Hespan and Oxyglobin on PO2 in Capillaries ............... 41 
Red Blood Cell POz and Comparisons with Hematocrit. Total Hemoglobin 
Concentration. and Plasma Hemoglobin Concentration .......................................... 41 
Red Blood Cell PO2 and Hematocrit .................................................................... 41 
Red Blood Cell PO;? and Total Hemoglobin Concentration ................................. 45 
Red Blood Cell PO2 and Plasma Hemoglobin Concentration .............................. 48 
Plasma Gap PO2 and Comparisons with Hematocrit. Total Hemoglobin 
Concentration. and Plasma Hemoglobin Concentration .......................................... 48 
Plasma Gap PO2 and Hematocrit .......................................................................... 48 
....................................... Plasma Gap PO2 and Total Hemoglobin Concentration 51 
.................................... Plasma Gap PO2 and Plasma Hemoglobin Concentration 53 
Red Blood Cell . Plasma Gap PO2 Difference (AP02) and Comparisons with 
Hematocrit. Total Hemoglobin Concentration. Plasma Hemoglobin Concentration. 
and Red Blood Cell PO2 ........................................................................................... 53 
............................................................................................ APO2 and Hematocrit 53 
AP02 and Total Hemoglobin Concentration ......................................................... 56 
AP02 and Plasma Hemoglobin Concentration ...................................................... 56 
AP02 and Red Blood Cell PO2 .............................................................................. 59 
Results of Statistical Analysis ....................................................................................... 59 
DISCUSSION ................................................................................................................... 61 
Prior Documentation on Erythrocyte-Associated Transients. Hemodilution and 
Hemoglobin-Based Oxygen Carriers ............................................................................ 62 
Phosphorescence Amplitude and Light Transmission .................................................. 62 
Effects of Hemodilution on Systemic Parameters ........................................................ 64 
Summary of Experimental Results for Mean Arterial Pressure and Hematocrit ..... 64 
Explanation of Variation in Results .......................................................................... 66
Summary of Experimental Results for Mean Arterial Pressure and Plasma 
Hemoglobin Concentration ....................................................................................... 66 
Results and Comparisons in Prior Investigations for Mean Arterial Pressure ........ 66 
Effects of Hemodilution with Hespan and Oxyglobin on Capillary PO2 ..................... 67 
Summary of Experimental Results for Red Blood Cell PO2 ..................................... 67 
Summary of Experimental Results for Plasma Gap PO2 .......................................... 69 
Summary of Experimental Results for AP02 .......................  ................................ 70 
Interpretation of Results and Comparison with Prior Investigations ............................ 71 
Summary and Conclusion ............................................................................................. 75 
Recommendations for Future Studies ........................................................................... 77 
............................................................................................................. BIBLIOGRAPHY 79 
VITA ................................................................................................................................. 85 
LIST OF TABLES 
Table 1. Number of animals and capillaries used for systemic and PO2 determination. 18 
Table 2. Mean (i standard deviation) systemic data for all animals. .............................. 39 
Table 3. Mean (h standard deviation) systemic data for animal sub-group ..................... 42 
Table 4. Mean (h standard deviation) partial pressure of oxygen data for animal sub- 
........................................................................................................................ group. 44 
vii 
LIST OF FIGURES 
Figure 1 . Representative Phosphorescence Intravital Microscope Setup ........................ 23 
Figure 2 . Representative phosphorescence decay curve ................................................... 28 
Figure 3 . Example of P02. light transmission. and phosphorescence amplitude versus 
time ........................................................................................................................... 35 
Figure 4 . Plot of phosphorescence amplitude versus light transmission ......................... 36 
Figure 5 . Plots of partial pressure of oxygen versus phosphorescence amplitude and light 
. . 
transmission .............................................................................................................. 37 
Figure 6 . Plot of mean arterial pressure versus hematocrit for hemodilution with Hespan 
and Oxyglobin ........................................................................................................... 40 
Figure 7 . Plot of plasma hemoglobin concentration versus mean arterial pressure for 
hemodilution with Oxyglobin ................................................................................... 43 
Figure 8 . Plot of red blood cell partial pressure of oxygen versus hematocrit for 
hemodilution with Hespan and Oxyglobin ............................................................... 46 
Figure 9 . Plots of red blood cell partial pressure of oxygen versus total hemoglobin for 
.............................................................................................. Hespan and Oxyglobin 47 
Figure 10 . Plots of red blood cell partial pressure of oxygen versus plasma hemoglobin 
for Hespan and Oxyglobin ........................................................................................ 49 
Figure 1 1 . Plot of plasma gap partial pressure of oxygen versus hematocrit for 
hemodilution with Hespan and Oxyglobin ............................................................... 50 
Figure 12 . plots of plasma gap partial pressure of oxygen versus total hemoglobin for 
Hespan and Oxyglobin .............................................................................................. 52 
Figure 13 . Plots of plasma partial pressure of oxygen versus plasma hemoglobin for 
Hespan and Oxyglobin .............................................................................................. 54 
Figure 14 . AP02 versus hematocrit .................................................................................. 55 
Figure 15 . AP02 versus total hemoglobin concentration ................................................. 57 
............................................. Figure 16 . AP02 versus plasma hemoglobin concentration 58 
. . . 
V l l l  
Figure 17. APO2 versus red blood cell partial pressure of oxygen. ................................. 60 
Figure 18. Plots of Bimodal PA Signal ............................................................................ 65 
LIST OF ABBREVIATIONS 
a 
ANH 
B 
P 
C H ~  
cm 
D 
Da 
"C 
6 
AP02 
Ax 
dl 
EATS 
EDRF 
FCD 
FFT 
2,3-diphosphoglycerate 
cross-sectional area 
amplitude of the fast post-excitation transient 
oxygen solubility coefficient 
acute normovolemic hemodilution 
baseline offset 
proportionality factor 
oxygen binding capacity of hemoglobin 
centimeter 
free diffusion coefficient for a particular molecule 
Dalton 
degrees Celsius 
half width of the PO* distribution 
partial pressure difference 
diffusion distance 
deciliter 
erythrocyte-associated transients 
endothelial derived relaxing factor 
functional capillary density 
fast Fourier transform 
gram 
HB2 
HBOC 
[Hbl 
[HbIplasma 
[H~]RBc 
HbOz 
Hct 
HDl 
hemoglobin-based oxygen carrier value at hemodilution Step 1 
hemoglobin-based oxygen carrier value at hemodilution Step 2 
hemoglobin-based oxygen carrier 
total hemoglobin concentration 
plasma hemoglobin concentration 
concentration of hemoglobin in a single red blood cell 
oxyhemoglobin 
systemic hematocrit 
hemodilution Step 1 
hemodilution Step 2 
final systemic hematocrit 
initial systemic hematocrit 
Hespan value at hemodilution Step 1 
Hespan value at hemodilution Step 2 
hertz 
amplitude of the phosphorescence signal at t = 0 
magnitude of the phosphorescence signal 
quantity of oxygen moved per unit time 
rate constant 
kilo Dalton 
kg 
kHz 
k4 
k4 
LT 
M 
MAP 
MCHC 
metHb 
P1 
Pm 
mg 
ml 
mM 
mmHg 
min 
N 
n 
nJ 
NLA 
kilogram 
kilohertz 
quenching coefficient 
second-order tae constant for phosphorescence decay 
light transmission 
mean POz 
mean arterial pressure 
mean corpuscular hemoglobin concentration 
met-hemoglobin 
microliter 
micrometer 
microseconds 
milligram 
milliliter 
milimolar 
milimeters of mercury 
minute 
number of animals 
number of capillaries 
nanoj oules 
nitro-L-arginine 
nanometer 
xii 
NO 
NO3- 
NOD 
0 2  
PA 
PaCO2 
Pa02 
PC02 
PC02 
Pd 
Pd-MTCPP 
PE- 10 
PE-20 
PE-240 
PE-50 
PE-90 
PEG 
PFCs 
PG 
PMT 
PO2 
P Q M 
nitric oxide 
nitrate 
nitric oxide dioxygenation 
oxygen 
phosphorescence amplitude 
systemic arterial partial pressure of carbon dioxide 
Systemic arterial partial pressure of oxygen 
partial pressure of carbon dioxide 
mean capillary partial pressure of oxygen 
palladium 
meso-tetra-(4-carboxypheny1)-porphyrin 
size 10 polyethylene tubing 
size 20 polyethylene tubing 
size 240 polyethylene tubing 
size 50 polyethylene tubing 
size 90 polyethylene tubing 
polyethylene glycol 
perfluorocarbons 
plasma gap 
photomultiplier tube 
partial pressure of oxygen 
phosphorescence quenching microscopy 
xiii 
SaO2 
SFH 
convective flow of oxygen 
diffuse flow of oxygen 
red blood cell 
arterial oxygen saturation 
stroma-free hemoglobin 
fractional oxygen saturation of red blood cell hemoglobin 
red blood cell supply rate 
time from the beginning of phosphorescence decay 
lifetime of the fast post-excitation transient 
phosphorescence lifetime 
lifetime of phosphorescence decay in the absence of 0 2  
effective blood volume associated with hemodilution 
volume of a single red blood cell 
body weight of the animal 
ABSTRACT 
ERYTHROCYTE-ASSOCIATED TRANSIENTS IN CAPILLARY PO2 IN 
THE RAT SPINOTRAPEZIUS MUSCLE DURING HEMODILUTION 
WITH HESPAN AND A HEMOGLOBIN-BASED OXYGEN CARRIER 
By Matthew C. Barker 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University 
Virginia Commonwealth University, 2005 
Advisor: Roland N. Pittman, Ph.D. 
Department of Physiology 
Hemoglobin-based oxygen carriers for use as transfusion fluids have emerged as a 
leading technology directed at stemming shortages of a safe blood supply and providing a 
readily available resuscitation fluid in various trauma situations. The purpose of this 
investigation was to determine the effects of isovolemic hernodilution with Hespan and a 
hemoglobin-based oxygen carrier (HBOC) on erythrocyte-associated transients (EATs) in 
capillary PO2. The particulate nature of blood flow in capillaries, when observed from a 
stationary observation point, results in fluctuations of PO2 as alternating red blood cells 
and plasma gaps move through the detection region. Therefore, through experimental 
methods which provided the necessary temporal and spatial resolution required to make 
such measurements, EATs can be observed and corresponding PO2 fluctuations can be 
determined. The spinotrapezius muscle in sixteen Sprague-Dawley rats was exteriorized 
for intravital microscopy measurements in capillaries. Capillary PO2 was measured using 
Pd-porphyrin phosphorescence quenching microcopy. The hemodiluents used in 
isovolemic hemodilution included Hespan, a non-oxygen carrying plasma expander, and 
OxyglobinB, a HBOC. Two isovolemic hemodilution steps were performed, reducing the 
systemic hematocrit to an average of 27.5% after the first step and 13.5% after the second 
step. Results showed that erythrocyte-associated transients in PO2 can be observed in the 
rat spinotrapezius with significant differences occurring between red blood cell and 
plasma gap PO2 under control conditions, isovolemic hemodilution with Oxyglobin after 
step one, and isovolemic hemodilution with Hespan after step two. This study concludes 
that EATs are observable and POz transients relating to EATs can be measured in the rat 
spinotrapezius muscle. Furthermore, it can be concluded that the HBOC Oxyglobin 
caused a decrease in erythrocyte-associated capillary POz transients, as well as a general 
decrease in capillary PO2. In addition, this study concludes that erythrocyte-associated 
capillary PO2 transients can best be observed under control conditions and after step two 
of isovolemic hemodilution with Hespan. 
INTRODUCTION 
The Blood and Circulation 
Oxygen is a fundamental component required to sustain life of most cells in the 
body of all mammals. The metabolic need for oxygen of cells in tissues requires the 
transport of oxygen to those sites. Mammals appear to have evolved in accordance with 
the principles of symmorphosis (i.e., a state of structural design corresponding to 
functional needs resulting from regulated morphogenesis), possessing tissues, blood, and 
a circulatory structure to carry out these essential functions of life (Weibel 1984). 
Blood Composition 
Circulating blood volume accounts for approximately 7% of body weight. About 
55% of this volume is plasma and the other 45% is composed of blood cells. Dissolved 
in the plasma is a complex solution of gases, salts, proteins, carbohydrates, and lipids 
(Beme and Levy 1998). In the blood cell component there are approximately between 
7,000 and 12,000 white cells, between 150,000 and 400,000 platelets, and between 4.5 
and 5.5 million red blood cells in a volume of a cubic millimeter of blood (Nucci and 
Abuchowski 1998). These two components perform multiple tasks including: the 
transport of nutrients, oxygen, carbon dioxide and waste products; the delivery of 
hormones, leukocytes, and platelets to their sites of action; and the distributions of water, 
other solutes, and heat (Beme and Levy 1998; Nucci and Abuchowski 1998). 
Red Blood Cells and Hemoglobin 
Red blood cells, or erythrocytes, are nonnucleated, terminally differentiated cells 
that possess an average lifetime of 120 days. They are flexible, biconcave disks with an 
average diameter of 7 pm (Berne and Levy 1998). Erythrocytes are hollow vesicles filled 
with molecules called hemoglobin that have the capacity to carry oxygen. Hemoglobin 
turns such a hollow vesicle into a discrete oxygen transporting package, with hemoglobin 
occupying approximately a quarter of each cell's internal volume (about 3 . 10.' ' glcell) 
(Weibel 1984). 
Hemoglobin (MW = 66,000 Da) is a protein tetramer with two a and two P 
polypeptide chains. Each polypeptide chain has an iron-containing heme group which is 
used to reversibly bind oxygen. Consequently, four molecules of oxygen can bind to 
each hemoglobin molecule (Weibel 1984; Chang 1999). 
As individual oxygen molecules bind to a subunit of the hemoglobin molecule, its 
configuration is altered, allowing for increased binding affinity of each subsequent 
oxygen molecule, until all four binding sites are occupied (i.e., positive cooperativity). 
This cooperativity results in a sigmoidally shaped binding curve that can undergo shifts 
influenced by local factors thereby affecting the oxygen affinity of hemoglobin. These 
factors include PC02, pH, temperature, and 2,3-diphosphoglycerate (2,3-DPG) 
concentration (Berne and Levy 1998; Costanzo 1998). 
Oxygen is transported in the blood in two forms: 1) dissolved in the plasma and 2) 
bound to hemoglobin. Dissolved oxygen comprises approximately 2% of the total 
oxygen content of blood and is inadequate to supply the demands of the tissues. The 
remaining 98% of the oxygen is reversibly bound to hemoglobin, so that the oxygen 
content of blood is principally determined by the oxygen binding capacity and the 
concentration of hemoglobin (Costanzo 1998). 
In the lungs, there is a reciprocal exchange of carbon dioxide and oxygen, at 
different sites, as hemoglobin molecules flow through the pulmonary capillaries adjacent 
to alveolar gas. Carbon dioxide, a waste product of cellular respiration, is unloaded and 
oxygen binding to the heme groups of the hemoglobin takes place. From there, oxygen is 
delivered to cells for utilization as the final electron acceptor in oxidative 
phosphorylation (Weibel 1984; Costanzo 1998). 
The Circulation and Oxygen Transport in Blood Vessels 
William Harvey (1578-1657) was the first person to accurately describe the 
overall workings of the circulatory system. Prior to Harvey, there existed multiple 
explanations as to the purpose, source and directional flow of blood, none of them 
considering a unidirectional circuit. Galenic physiology taught that there were two types 
of blood, the venous and the arterial, each with distinct pathways, independent sources, 
and hnctions. Harvey established that the blood must constantly move in a circuit 
through the large vessels stemming from the heart and then to the lungs and tissue and 
back to the heart again (Porter 1998). What he could not understand then was the 
complex system involving vascular networks and oxygen delivery. 
In general, blood is propelled from the heart through the arteries (main 
distribution vessels) to capillaries (primary exchange vessels) and then into veins 
(collecting vessels) which lead back to the heart (Weibel 1984). This is not much more 
information than Harvey gleaned from his studies. What he could not see then and what 
has become the location and focus of many studies in the circulatory system today is the 
microcirculation. The multiple networks are comprised of branching arterioles and still 
finer networks of capillaries, vessels whose walls are comprised of only a single layer of 
endothelial cells and whose lumen permits red blood cells to pass only in single file 
(Berne and Levy 1998; Costanzo 1998). 
Capillary structure is maximized for the local diffusion of oxygen down a gradient 
into the mitochondria1 sinks created by oxidative phosphorylation (Weibel 1984). Their 
walls are thin and they exhibit the greatest surface-area-to-volume ratio in the 
microcirculation (Costanzo 1998). In addition, red blood cell velocity is low and gas 
diffusion distance is minimized by the close proximity of capillaries to surrounding tissue 
cells (Pittman 1995). 
Convection and Diffusion 
Oxygen is transported via convection (i.e., the movement of oxygen in blood by 
bulk flow) and diffusion (i.e., molecular movement of oxygen in the fluid or gas phase 
down partial pressure gradient) (Weibel 1984; Pittman 2000). Convective flow of 
oxygen can be expressed by the following (Pittman 1995): 
Equation 1 
where CHb is the oxygen binding capacity of hemoglobin (i.e. the maximum amount of 
oxygen that is able to bind to hemoglobin per unit volume of blood (Costanzo 1998), 
[H~]RBc is the concentration of hemoglobin in a single red blood cell, VRBC is the volume 
of a single red blood cell, SRRBC is the red blood cell supply rate (cellsls), and SO2 is the 
fractional oxygen saturation of the red blood cell hemoglobin. 
Diffusive flow of oxygen ( ~ 0 2 ~ ' ~ ~ )  can be determined by the application of 
Fick's Principle, a statement of the conservation of mass, by the following: 
Equation 2 
DIFF - CONV Q02 - ~ 0 2 " ~ ~ ~  (upstream) - QO2 (downstream) 
where ~ 0 2 " ~ ~ "  is convective flow of oxygen (Pittman 1995; Pittman 2000). 
Alternatively, capillary diffusion can be described more directly as the radial diffusive 
flux of oxygen as: 
Equation 3 
~0~~ = - DaAAP021Ax 
where ~ 0 2 ~  is the quantity of oxygen moved per unit time, D is the free diffusion 
coefficient for a particular molecule, a is the oxygen solubility coefficient, A is the cross- 
sectional area, and AP02/Ax is the partial pressure gradient (i.e., AP02 is the partial 
pressure difference of oxygen and Ax is the diffusion distance) (Berne and Levy 1998; 
Pittman 2000). The ability for diffusion to function as the primary mechanism in the 
exchange of gases, substances, and waste products between the capillaries and the tissue 
cells for the entire body, despite large diffusion distances of 80 pm compared to 0.5 pm 
in pulmonary capillaries, is due to the large capillary surface area and capillary 
recruitment (Berne and Levy 1998). 
Artificial Oxygen Carriers 
Historical Background 
The desire to find safe and effective blood substitutes dates back to the mid-16~~ 
century to the early 17th century (Scott, Kucik et al. 1997; Creteur, Sibbald et al. 2000). 
During this time Christopher Wren had been attempting to introduce medicinal liquors 
into the bloodstream, believing that the alcoholic spirits could substitute for the vital 
"spirit" of the blood (Porter 1998; Creteur, Sibbald et al. 2000). Jean-Baptiste Denis 
performed .the first documented successful human-to-human blood transfusion in 1667 
(Nucci and Abuchowski 1998). 
Modern scientific approaches to replace blood began to be successful in the early 
1900s with a better understanding of allogeneic blood transfusion and the function of red 
blood cells (Kim and Greenburg 2004). More recently, concerns of long term storage, 
supply limitations, and avoidance of disease transmission have fueled the need to develop 
blood substitute possibilities. Numerous studies performed throughout the early to mid- 
1900s focused attention on infusing hemoglobin solutions for purposes of trauma 
resuscitation to help restore oxygen carrying capacity lost through hemorrhagic shock 
(Creteur, Sibbald et al. 2000). Although these investigations resulted in an unexplained 
pressor response, altered renal function, and hemoglobinuria, among others, the stage was 
set for the development of artificial oxygen carriers (Scott, Kucik et al. 1997; Creteur, 
Sibbald et al. 2000). 
Major Approaches to Artificial Oxygen Carriers 
Under conditions of moderate blood loss where oxygen delivery is not seriously 
compromised, intravascular blood volume can be replaced with non-oxygen carrying 
plasma expanders. Plasma expanders come in two forms, either as a crystalloid (e.g., 
isotonic saline, Ringer's lactate) or as a colloid (e.g., human serum albumin, dextran, 
hetastarch) (Kim and Greenburg 2004). Under conditions of severe blood loss, where 
oxygen transport capacity has been reduced below critical levels, an oxygen carrier must 
be infused to sustain normal cellular function. 
The purpose of artificial oxygen carriers is to act solely as an oxygen-carrying, 
volume-replacement solution (Scott, Kucik et al. 1997). The ideal product should have 
all of the important properties of red blood cell transfusions including: 1) high oxygen 
carrying capacity; 2) transport of oxygen at normal physiological oxygen tensions; 3) 
desirable elimination characteristics; 4) low incidence of side effects when properly 
screened and administered (Dietz, Joyner et al. 1996). In addition, undesirable properties 
should be excluded such as: 1) relatively short shelf-life; 2) antigenicity testing; 3) 
transfusion reactions; 4) dependence on a limited donor pool; 5) infectious disease 
transmission; 6) immune system suppression (Dietz, Joyner et al. 1996; Scott, Kucik et 
al. 1997; Ketcham and Cairns 1999). 
Although such a product has been sought for several centuries, it was not until the 
1980s and significant investment by the United States military that commercial 
development of such a product began (Winslow 2000). Since then, two major 
approaches to artificial oxygen carriers have emerged: bio-artificial carriers and synthetic 
carriers. Of these, hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon 
emulsions (PFCs) are the most promising candidates (Spahn 2000; Kim and Greenburg 
2004). 
Perfluorocarbons 
PFCs are synthetic aromatic carbon-fluorine compounds characterized by a high 
gas-dissolving capacity, low viscosity, and biological inertness. These compounds are 
emulsified in solution with an agent (58% perfluorooctyl bromide and 2% perluorodecyl 
bromide) that allows its dispersal in the blood (Nucci and Abuchowski 1998; Spahn and 
Pasch 200 1). PFCs, unlike hemoglobin molecules, do not bind oxygen, but rather they 
increase the solubility of oxygen in the plasma (Chang 1999; Ketcham and Cairns 1999). 
The oxygen capacity of PFCs is linearly related to PO2, making efficacy of such a 
solution dependent on the amount of oxygen available from inspired air (Goodnough, 
Scott et al. 1998). 
Hemoglobin-based Oxygen Carriers 
Currently, HBOCs are developed from stroma-free hemoglobin (SFH). SFH is 
derived from human or animal (typically bovine) red blood cells that have been lysed and 
the stroma removed through chemical methods, centrifugation, andlor filtration (Haney, 
Buehler et al. 2000). However, unmodified SFH has a high oxygen affinity, elevated 
intravascular oncotic pressure, and is rapidly cleared through the kidneys (Ketcham and 
Cairns 1999; Winslow 2000). Furthermore, the tendency for the hemoglobin tetramer to 
dissociate into dimers often results in renal toxicity. For these reasons, chemical or 
genetic modifications need to be made to create the desirable oxygen offloading 
characteristics, extend the intravascular half-life, and curtail renal toxicity (Kim and 
Greenburg 2004). 
Hemoglobin-based Oxygen Carriers 
ModiJcations of the Hemoglobin Molecule 
The high oxygen affinity and subsequent inability of unmodified HBOCs to 
efficiently deliver oxygen at tissue sites is due to the loss of 2,3-DPG during the 
purification process (Kim and Greenburg 2004). Normally, 2,3-DPG has a specific 
binding cleft within the tetrameric hemoglobin molecule which stabilizes the structure in 
the deoxy form and promotes positive cooperativity. Without 2,3-DPG oxygen binds to 
hemoglobin in the lungs, but will not be unloaded in the tissue (Nucci and Abuchowski 
1998; Haney, Buehler et al. 2000). An alternative approach to avoid high oxygen affinity 
is to utilize low oxygen affinity bovine hemoglobin as a starting material. Contrary to 
human hemoglobin, the affinity of bovine hemoglobin for oxygen is not dependent on 
2,3-DPG and can be modified to achieve the desired oxygen affinity and circulation time 
(Lee, Atsumi et al. 1989) 
A variety of chemical modifications can be made to SFH to adjust the oxygen 
affinity to one resembling human encapsulated hemoglobin and to prevent other 
undesirable side effects. One method is to bind chemical subgroups to SFH to act in 
place of 2,3-DPG (Poly-SFH-P) (Ketcham and Cairns 1999). Another method is to 
cross-link the dimers of the hemoglobin tetramer through covalent bonds either 
intramolecularly or intermolecularly (commercial examples include diaspirin cross-linked 
hemoglobin and rHb1. I). Polymerization is another technique used to link tetramers 
together into longer chains (commercial examples include Poly-SFH-P and Oxyglobin), 
increasing the overall size of the structure and reducing the possibility of renal filtration 
and consequent renal damage (Nucci and Abuchowski 1998; Chang 1999; Ketcham and 
Cairns 1999). Conjugating hemoglobin with a polymer such as polyethylene glycol 
(PEG) also increases the size of the structure, reduces renal damage, and protects the 
molecule from renal excretion (Nucci and Abuchowski 1998; Kim and Greenburg 2004). 
More recently, recombinant human hemoglobin is produced by genetically engineered 
Escherichia coli bacteria, where the subunits are fused together to prevent tetramer 
disassociation (Chang 1999). Lastly, human or animal SFH can be encapsulated in a 
phospholipid vesicle, resulting in hemoglobin concentrations and reversible oxygen 
binding similar to that of human blood (Kim and Greenburg 2004). 
Physiological Effects of HBOCs 
A number of physiological side effects and negative attributes have been observed 
with HBOCs, despite successful modifications. Animals that have received hemoglobin 
solutions maintain normal oxygen consumption and carbon dioxide production, as well as 
cardiac output, yet there are increases in mean arterial pressure, pulmonary artery 
pressure, and systemic vascular resistance (Dietz, Joyner et al. 1996). The hypertensive 
effects are caused by vasoconstriction, with studies observing up to 35% increases in 
diastolic and systolic pressures and 45% increases in systemic and pulmonary vascular 
resistance (Goodnough, Scott et al. 1998). Mechanisms of the vasopressor effect have 
been attributed to nitric oxide (NO) "scavenging" by hemoglobin, excess oxygen delivery 
to peripheral tissues, direct effects on peripheral nerves, the oxidative properties of 
hemoglobin (Sanders, Ackers et al. 1996), or endothelin release (Gulati, Sharma et al. 
1996). However, most investigators have focused on NO interactions with hemoglobin. 
NO, once referred to as endothelial derived relaxing factor (EDRF), normally 
induces vasodilation, thereby reducing blood pressure by the relaxation of vascular 
smooth muscle. With the addition of SFH, NO is believed to interact with bound oxygen 
in a process called NO dioxygenation (NOD) resulting in met-hemoglobin (metHb) and 
nitrate (NO3]. This process occurs rapidly and in vessels creates a diffusion gradient as 
the hemoglobin molecules stream along vessel walls acting as an NO "sink" reducing NO 
diffusion to smooth muscle receptors (Olson, Foley et al. 2004). This is known as NO 
scavenging. Studies have also suggested unpolynierized hemoglobin molecules may 
penetrate into the interstitial space (extravasation), resulting in a more direct interference 
with normal vasomotor activity (Ketcham and Cairns 1999; Spahn 2000; Olson, Foley et 
al. 2004). 
NO scavenging has also been found to cause aggregation of platelets (Ketcham 
and Cairns 1999). The usual antiplatelet role of NO is removed due to scavenging by 
hemoglobin, resulting in increased platelet aggregation at sites of vascular injury 
(Ketcham and Cairns 1999; Creteur, Sibbald et al. 2000). However, hemodilution up to 
50% of blood volume replacement with a HBOC should not significantly impair normal 
coagulation mechanisms (Kim and Greenburg 2004). Other contraindications of note 
include gastrointestinal distress and neurotoxicity (Ketcham and Cairns 1999; Kim and 
Greenburg 2004). 
Another function of NO to consider is its ability to regulate respiration (Sarti, 
Giuffre et al. 2003). NO reversibly inhibits cytochrome c oxidase, the terminal electron 
acceptor in the mitochondrial respiration chain, by competing with oxygen (Cleeter, 
Cooper et al. 1994; Schweizer and Richter 1994). Nanomolar concentrations of NO have 
been found to reversibly inhibit cytochrome c oxidase which inhibits normal 
mitochondrial function causing oxygen consumption to decrease (Brown and Cooper 
1994). Conversely, it has been demonstrated that the suppression of NO synthesis and 
therefore a decreased presence of NO available to act on the mitochondrial respiratory 
chain resulted in large increases in oxygen consumption (Shen, Hintze et al. 1995). 
Possible Indications for HBOCs 
The clinical applications of HBOCs are varied, but much focus is placed on 
utilization in the surgical setting, trauma medicine, and military applications. Purposed 
applications include use in situations of the following: shocldtrauma, hemodilution, 
perioperative use, perfusion of ischemic organs, septic shock, organ transplantation, and 
tumor therapy (Dietz, Joyner et al. 1996; Creteur, Sibbald et al. 2000). In addition, 
clinical application of HBOCs can be found in stroke, sickle cell crises, anemia, and 
patients with multiple red cell surface antibodies (Dietz, Joyner et al. 1996; Chang 1999). 
HBOCs are ideal for military and trauma settings as a result of long shelf life (> 1 year) at 
room temperature, avoidance of the need to cross-match patients, lack of adverse 
transfusion reactions, and minimized risk of disease transmission (Goodnough, Scott et 
al. 1998). 
Hemodilution 
Hemodilution refers to the increase in plasma volume resulting in a reduced 
concentration of red blood cells in the blood (hematocrit). Isovolemic hemodilution is 
the process of withdrawal of a specified volume of blood and replacement with an equal 
volume of fluid, either crystalloids, colloids, or artificial oxygen carrier. Hemodilutions 
up to 50% of the red blood cell mass and down to a hematocrit of 9% is well tolerated in 
physiological systems and the microcirculation (Habler and Messmer 2000; Tsai and 
Intaglietta 2001). The clinical significance of this procedure is that it can significantly 
reduce blood transfusion requirements during surgery and can be used in the treatment of 
acute ischemic stroke and peripheral arterial occlusive disease, among others (Spahn, 
Leone et al. 1994). 
Acute nomovolemic hemodilution (ANH) is often carried out in the perioperative 
setting. During ANH, a patient's blood is removed immediately before or during surgery 
and replaced with another fluid (Fakhry and Sheldon 1995; Scott, Kucik et al. 1997). 
Both isovolemic hemodilution and ANH, at mild to moderate levels, result in an 
increase in cardiac output and blood flow velocity through the decrease of blood 
viscosity. These physiological alterations constitute a compensatory mechanism for the 
decrease in arterial oxygen content, so that oxygen delivery is maintained (Spahn, Leone 
et al. 1994; Tsai and Intaglietta 2001). 
Erythrocyte-associated Transients in PO2 
Blood flows in large vessels as a homogeneous mixture where the components, 
plasma and red blood cells, cannot be easily distinguished. This trend continues as the 
bulk flow of blood moves from arteries to arterioles and finally into capillaries. It is at 
the capillary level that the individual red blood cells can be easily discerned from the 
plasma spaces around them. The phrase "particulate (or discrete) nature of blood flow" 
has been used to describe this phenomenon in capillaries. 
In recognition of this phenomenon, in 1977 Hellums proposed the term 
"erythrocyte-associated transients" (EATS) (Hellums 1977; Hellums, Nair et al. 1996) 
which refers to the fluctuations of POz in a capillary caused by the alternate passage of 
individual red blood cells and plasma gaps. Since then, many mathematical models have 
been developed to explore the implications of these transients (Federspiel and Sarelius 
1984; Federspiel and Pope1 1986; Groebe and Thews 1989; Pope1 1989; Wang and Pope1 
1993; Hellums, Nair et al. 1996; Kisliakov 1996; Eggleton, Roy et al. 1998). 
These transients are a manifestation of the POs gradients between the plasma and 
red blood cells with varying amplitudes dependent on cell spacing, shape, and 
orientation. The PO2 gradient is also affected by the diffusion gradient that exists for 
oxygen outside of the capillary. In many mathematical models, intracapillary resistance 
has been shown to be a sizable contribution to overall resistance to oxygen transport. 
This stems, presumably, from the low solubility of oxygen in the plasma, which hinders 
diffusive oxygen movement down its gradient from the red blood cell through the 
surrounding plasma sheath and plasma gaps into the tissue (Golub and Pittman 2005; 
Pittman 2005). 
Purpose of the Present Study 
In this study 1 set out to observe erythrocyte-associated transients in capillary POz 
in the rat spinotrapezius muscle under conditions of isovolemic hemodilution with a non- 
oxygen carrying plasma expander, Hespan, and a hemoglobin-based oxygen carrier, 
Oxyglobin. When using Hespan as the hemodiluent, one might expect cell spacing in 
capillaries to increase and intracapillary resistance to oxygen offloading to also increase 
as hematocrit and total hemoglobin concentration decreased with isovolemic 
hemodilution. A direct consequence of this would be more pronounced transients of 
EATS and therefore a greater difference between red blood cell PO2 and plasma PO2. 
Conversely, when using an artificial oxygen carrier as the hemodiluent under similar 
conditions of isovolemic hemodilution, one might expect an increase in cell spacing but a 
decrease in intracapillary resistance to oxygen offloading as a result of an increased 
contribution of an oxygen carrier to the plasma. This, in turn, would result in a reduction 
in EAT transients. 
The purpose of the present study is to apply a detection method previously used 
for EATs in the rat mesentery to a skeletal muscle model to answer the following 
questions: 1) What happens to EATs with the addition of a non-oxygen carrying plasma 
expander, like Hespan, under isovolemic hemodilution?; 2) What happens to EATs with 
the addition of an oxygen-carrying plasma expander such as a HBOC under isovolemic 
hemodilution? 
MATERIALS AND METHODS 
Anesthesia and Animal Preparation 
Sixteen female Spraque-Dawley rats (Harlan, Indianapolis, IN; weight of 241.8 
(SD 14.7) grams, age of 83.4 (SD 6.3) days were housed in plastic isolation containers 
with continual ventilation in a climate-controlled room kept at 20-23 "C with a 
continuous 12 hr: 12 hr light-dark cycle. Laboratory chow and water were provided ad 
libitum under the supervision of a certified animal care technician. 
Due to technical limitations, it was not possible to obtain capillary PO2 values 
from all animals for which systemic data were obtained. Table 1 catalogs the number of 
animals in the groups where systemic and capillary data were acquired. 
Initial anesthesia with a combination of Acepromazine (2.5 mglkg) and Ketamine 
(75 mglkg) was administered via intraperitoneal (i.p.) injection. A continuous infusion of 
Saffan (Alphaxolone 9 mglml and Alphadolone 3 mglml, Schering-Plough Animal 
Health, Hertfordshire, England) was used for supplemental anesthetic maintenance 
administered intravenously (i.v.) via the cannulated right jugular vein using an infusion 
pump (Harvard Apparatus Co., Inc., Dover, Mass.) set at an average of .OOl88 (SD .001) 
mllmin. Upon conclusion of experimentation, the animals were euthanized by Euthasol 
(Pentobarbital 390 mglml and Phenytoin 50 mglml, Delmarva Laboratories, Inc., 
Midlothian, VA) administration of 0.4 mllkg. 
Table 1. Number of animals and capillaries used for systemic and POz 
determination. 
Control Step 1 Step 2 
Hespan 8/2/26 8/5/26 5/5/53 
HBOC 8/2/20 8/5/26 5/5/50 
Entries in the Table occur in the format: XNIZ where X = Number of animals with 
systemic data; Y = Number of animals with capillary data; Z = Number of capillaries 
analyzed from the data set. 
Hair between the ventral clavicles and mentum, ventral right groin, and dorsal 
regions was removed by electric shears, followed by a depilatory cream (Nair, Church 
and Dwight Co., Inc., Princeton, NJ). Afterward, the animal was placed in the supine 
position on a metal surgical platform with temperature regulation via automated 
electronic controls for cannulations and muscle exteriorization. 
Tracheal and Vascular Cannulations 
First, to ensure a patent airway and spontaneous room-air breathing, the trachea 
was cannulated using a 4 cm length of polyethylene tubing (PE-240, Clay Adams, 
Parsippany, NJ). Subsequent cannulation of the right jugular vein with PE-90 tubing and 
the left common carotid artery with PE-50 tubing allowed for continuous i.v. 
administration of Saffan and arterial pressure monitoring, respectively. Further 
cannulations of the left femoral vein and artery were performed using PE-20 and PE- 10 
tubing (Clay Adams, Parsippany, NJ), respectively, under a stereo microscope (Nikon 
SMZ660, Melville, NY). The femoral artery was used for the withdrawal of blood during 
the hemodilution procedure, blood sampling for arterial blood gas measurements (ABL 
705, Radiometer America Inc., Westlake, OH), and hemoglobin measurements 
(Radiometer OSM3, Radiometer, Crawley, West Sussex, UK). The femoral vein was 
utilized for Hespan or HBOC infusion and albumin-bound Pd-porphyrin 
phosphorescence probe injection. Heparinized saline (20 units of heparidml of normal 
saline) or continuous infusion ensured patency of all vascular lines. 
Spinotrapezius Preparation 
The use of intravital microscopy techniques require the surgical exteriorization of 
the spinotrapezius muscle first described by Gray (Gray 1973). A modification of Gray's 
technique was used in which a dorsal midline incision was made from the lumbar to the 
cervical region, exposing the underlying superficial connective tissue. The tissue was 
removed cautiously, taking care not to damage the thin strap muscle on the left lateral 
border running parallel to the spinotrapezius muscle. A pair of curved scissors was used 
to separate the muscle from the underlying muscle layers starting at the left lateral border 
towards the muscle insertion point on the scapular spine and continuing towards the distal 
end of thoracolumbar origination. 5-0 silk was sutured every 1 cm along the strap muscle 
as the muscle was separated to ensure minimal trauma to the spinotrapezius and to 
facilitate surgical and experimental muscle manipulation. The right lateral border was 
excised from the vertebral axis, liberating the muscle except from its scapular attachment, 
and likewise sutured. A low-temperature cautery device (Gemini RS-300, Roboz 
Surgical Instrument Co., Rockville, MD) was used to staunch any vascular bleeding 
during the exteriorization procedure and the tissue was kept moist with frequent 
application of normal saline. After exteriorization of the spinotrapezius the animal was 
placed on a thermostatic animal platform (Golub and Pittman 2003). 
Phosphorescence Intravital Microscope 
The preparation was observed with an Ortholux microscope (Leitz, Germany) 
configured for epi-illumination through a 100XJ1.30 objective (Leitz, Germany). 
Immersion oil was placed between the objective and the Saran covering the 
spinotrapezius muscle. 
Phosphorescence excitation was achieved with a TTL-modulated DPSS 532 nm 
laser (GMS1-038-15T, Lasermate Corp., Pomona, CA) which delivered 60 nJ for a 
duration of 10 ps to a 0.9 pm diameter point at 100 Hz. The laser light was reflected by a 
dichroic mirror (565 DCLP, Chroma Technology Corp., Rockingham, VT) into the 
objective lens, then focused onto the mid-plane of a capillary with an adjustable 
correction lens between the laser and the microscope. Off-axis alignment of the laser was 
used to eliminate reflection of laser light from the various optical surfaces. A 
photomultiplier tube (PMT; R3896 with high voltage socket HC 123-01, Hamamatsu 
Corp., Bridgewater, NJ) detected the emitted phosphorescence that was collected by the 
lOOX objective. A sliding mirror allowed for either video imaging or phosphorescence 
light collection with the PMT. A CCD camera (WAT-902B, Watec Co., Ltd., Japan) and 
a 5.6" monochrome LCD monitor (45M056, Imaging Solutions, Inc., Korea) where used 
for video imaging and indirect capillary observation. 
The signal from the PMT was directed to a modified amplifier (OP37EP, Analog 
Devices, Norwood, MA) designed to be a current-to-voltage converter outfitted with a 
precision analog switch (ADG419BN, Nonvood, MA) allowing it to be disabled during 
the laser pulse generation of 10 ps duration at 100 Hz. Therefore, each phosphorescence 
decay curve was recorded from the end of the 10 ps excitation pulse until practical zero 
was reached, a requirement for 12-bit resolution. The signal was directed from the 
current-to-voltage converter to a 12-bit analog-to-digital converter (PC-MIO- 16E-4, 
National Instruments, Austin, TX). The digital data were stored on a Dell PC (Round 
Rock, TX). 
Data acquisition was controlled by the "DualGetCurve" program written in 
LabVIEW (National Instruments, TX) and allowed sampling at 200 kHz with 400 data 
points per curve and 100 curves per measurement sequence. Origin 6.1 (OriginLab, 
Northampton, MA) was used to analyze acquired data. 
The laser light passing through the capillary was detected with a T-5 photodiode 
(Intor, Socorro, NM) integrated with a 532 nm laser line filter. The signal collected from 
the diode was converted to a voltage with Amplifier B and directed to the second channel 
of the analog-to-digital converter and stored in the PC. Both the phosphorescence and 
light transmission signals were monitored with an oscilloscope (72-3060, Tenma, 
Springboro, OH). 
Selection of a capillary for measurements, and positioning the focal plane of the 
laser was carried out under transillumination using an OG-570 filter (Edmund Optics, 
Barrington, NJ). During periods of capillary POz and light transmission (LT) 
measurement, background light sources were minimized to reduce any effect of stray 
light. Figure 1 is a schematic diagram of the phosphorescence quenching microscope 
setup described above. 
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Figure 1. Representative Phosphorescence Intravital Microscope Setup 
Solution and Probe Preparations 
Preparation of Albumin-bound Pd-porphyrin Phosphorescent Probe 
Preparation of 20 ml of albumin-bound phosphorescence probe solution (1 0 
mglml) required binding of 200 mg palladium meso-tetra-(4-carboxypheny1)-porphyrin 
(Pd-MTCPP; Oxygen Enterprises, Philadelphia, PA) to 1.32 g bovine serum albumin 
(BSA; Fraction V, Sigma, St. Louis, MO). Over a period of approximately 30 min the 
Pd-MTCPP was added to a 1 mM BSA solution and stored overnight. This solution was 
dialyzed in 1 mM polyvinylpyrrolidine solution (PVP; Sigma-Aldrich, Inc.) and 
SpectraIPor-4 membranes to eliminate any unbound Pd-MTCPP from solution. After 18 
hr the solution was removed from the dialysis membranes and filtered through a 
sterilization filter unit (Nalgene, Rochester, NY). Aliquots of 0.5 ml of the final probe 
solution were placed in microcentrihge tubes, flash frozen in liquid nitrogen, and 
promptly stored at -80 OC. 
Properties and Preparation of 0xyg1obinn 
Oxyglobinm (also known as HBOC-30 l), a bovine hemoglobin glutamer 
(Biopure, Cambridge, Mass.), is a 7.8 pH solution containing 13 gldl polymerized bovine 
hemoglobin in a modified lactated Ringer's solution with an osmolality of 300 mOsmIkg. 
The P5() for Oxyglobin is 35 mmHg. Less than 5% of the hemoglobin polymer solution is 
comprised of unstabilized tetramers, approximately 50% has a molecular weight between 
65 and 130 kD with no more than 10% having a molecular weight >500 kD. Oxyglobin 
can be stored at room temperature or refrigerated at 2-30 "C for up to 36 months. Plasma 
half-life is estimated to range between 18 and 43 hours for dosages of 10-30 mllkg in 
dogs. 
Heparinized Saline 
Heparinized saline was necessary to assure patency of cannulas with intravascular 
placement. The solution was prepared using 5 ml heparin solution (100 unitslml; Heparin 
Lock, BD, Franklin Lakes, NJ) per 20 ml0.9% NaCl normal saline solution. Only 1 ml 
syringes were used for each cannulated vessel. 
Hespan 
Hespan (Abbott Laboratories, Chicago, IL) belongs to the class of drugs called 
plasma volume expanders and consists of 6% hetastarch in a 0.9% sodium chloride 
solution. It is a nonpyrogenic, sterile fluid isosmotic with blood (3 10 mOsm/l) and has 
no significant oxygen-carrying capacity. 
POz Measurements 
Capillary Selection and Probe Administration 
Before the partial pressure of oxygen (PO2) was measured, each capillary 
considered had to meet the following specified selection criteria: 1) sufficient light 
transmission (LT) with evident red blood cell (RBC) fluctuations as observed on the 
oscilloscope, 2) continuous RBC flow, 3) surface capillary, and 4) three-dimensional 
capillary isolation from other microvessels, arterioles, and venules. After capillary 
selection, PO2 was determined in each capillary using the phosphorescence quenching 
method for intravital microscopy (Zheng, Golub et al. 1996). Measurements were made 
in the centerline of the capillary in a region of high epi-illumination and visual contrast. 
The phosphor probe (30 mglkg) was administered via the right femoral vein prior 
to taking measurements. Approximately one minute of equilibration time was allowed 
before initiation of PO2 measurements. 
Phosphorescence Quenching Microscopy (PQM) 
PO2 determination using PQM is based on 02-dependent quenching of 
phosphorescence from photoexcited Pd-porphyrin. The Stern-Volmer equation defines 
the relationship between phosphorescence lifetime (z) and PO2 as follows: 
Equation 4 
l / z  = l/z, + kqP02 
where z, (546 ps) is the lifetime of phosphorescence decay in the absence of 0 2  and k, is 
the quenching coefficient (3.06.10~ p s - l r n m ~ ~ - ' ) .  Phosphorescence decay curves were 
analyzed using a non-linear curve fitting the Rectangular distribution model in Origin 6.1 
software (Microcal Software Inc., Northampton, MA) as developed by Golub et al. 
(Golub, Pope1 et al. 1997): 
Equation 5 
where t (ps) is the time from the beginning of phosphorescence decay, I(t) (volt) is the 
magnitude of the phosphorescence signal, I(0) (volt) is the amplitude of the 
phosphorescence signal at t = 0, M (mmHg) is the mean PO2, 6 (mmHg) is the half width 
of the POz distribution, T (ps) is the lifetime of the fast post-excitation transient, A (volt) 
is the amplitude of the fast post-excitation transient and B (volt) is the baseline offset. 
Constants ko = 18.3.10~ ps-' and k, = 3.06.10~ p ~ - ~ r n r n ~ ~ ~ '  were determined by Zheng et 
al. (Zheng, Golub et al. 1996). A representative plot, Figure 2, illustrates this 
relationship. 
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Figure 2. Representative phosphorescence decay curve. 
The phosphorescence decay curve shown on a logarithmic scale is composed of 400 
connected data points taken at 200 kHz over 2000 ps. The decay curve was analyzed 
using a non-linear curve fitting the Rectangular distribution model and is shown here by 
the continuous line fit. 
Light Transmission, Phosphorescence Amplitude Measurements, and 
PO2 
In order to detect fluctuations of PO2 in the detection volume associated with the 
presence of RBCs or plasma gaps, light transmission (LT) and phosphorescence 
amplitude (PA) were measured. 
LT was measured via photodiode registration of the intensity of the laser light 
passing through a capillary and the data collected by the "DualGetCurve" program. 
Maximum PA was determined from analyzing the beginning of the decay curve after the 
end of the excitation pulse. The maximum amplitude of the phosphorescent signal is 
proportional to the amount of plasma present in the detection volume, because the probe 
is homogeneously dissolved in plasma and does not enter RBCs. This was demonstrated 
using densitometric scanning and phosphorescence imaging of the Pd-porphyrin probe 
location that detected the presence or absence of RBCs (Golub and Pittman 2005). 
Upon analysis, the maximum amplitude of the phosphorescence decay curve (PA) 
and the light transmittance pulses were averaged using the three highest points at the peak 
of each signal. Noise from LT, PA, and PO2 values was reduced by filtering the signal 
with a fast Fourier transform filter (FFT; Origin 6.1, OriginLab, Northampton, MA) with 
50 Hz and 20 Hz cutoff frequency filtering. 
Although 100 individual PO2 measurements were made over the 1 s time course, a 
system was derived to choose which capillaries and PO2 measurements to calculate 
across the 1 s data collection interval. Golub and Pittman (2005) made two conclusions 
that provided selection parameters for PO2 calculation: 1) high positive correlations 
between PA and LT predicted the presence of EATS; 2) PA and PO2 had a more 
significant negative correlation than LT and PO2 indicating PA is a more consistent 
predictor of whether or not a RBC is in the detection region. With these parameters in 
mind, capillary selection was based on the highest correlation coefficients for each 
condition. Furthermore, capillary PO2 for red blood cells and plasma gaps was 
determined using the ten lowest PA values and the ten highest PA values, respectively, 
from the 100 collected data points. This corresponds to the idea that high PA should 
indicate the presence of plasma in the detection volume and low PA should indicate the 
presence of a RBC in the detection volume. 
Of the total 3 19 capillaries that were measured, 201 capillaries were chosen to 
determine POz values corresponding to the combined 20 high and low PA values. Each 
of the PO2 calculations using Origin 6.1 (OriginLab, Northampton, MA) took 
approximately two minutes. 
Mean Arterial Pressure 
Mean arterial pressure (MAP) was continuously monitored from the right 
common carotid artery using the CyQ 1031301 acquisition and display system 
(CyberSense Inc., Nicholasville, KY). Specific measures of MAP were recorded under 
control conditions and after a 10 min stabilization period subsequent to each 
hemodilution step. 
Hernodilution Procedure 
Isovolemic hemodilution was accomplished by the exchange of a given volume of 
blood with an equal volume of fluid (e.g., colloid, crystalloid, artificial oxygen carrier), 
resulting in decreased hematocrit, while maintaining a constant total blood volume. 
During this study, a two step withdrawallinfusion process was utilized with each step 
taking approximately forty-five minutes to complete. Additionally, each of these steps 
was reached by dividing the hemodilution volumes into four discrete withdrawallinfusion 
volumes. 
Isovolemic hemodilution was achieved through the withdrawal of blood from the 
right femoral artery followed by infusing the hemodiluent into the right femoral vein. 
The hematocrit of each animal was systematically lowered through two hemodilution 
steps: from 39.5 * 2.7 % (Control, mean * SD) to hematocrit of 27.5 * 2.8 % (Step 1, 
mean SD for both hemodiluents) and then to a hematocrit of 13.5 h 2.1 % (Step 2, 
mean * SD for both hemodiluents). 
In using this "discrete" method of hemodilution the effective blood volume 
associated with hemodilution, Ve, was initially determined by: 
Equation 6 
VB = P o  WB 
where /? is a proportionality factor in mllg and WB is the body weight of the animal in 
grams. A proportionality factor of 0.06 mllg was used for these experiments. 
Determination of initial systemic hematocrit, HI, and final systemic hematocrit, 
HF, was achieved through a centrifuged 75 pl sample collected from the right femoral 
arterial line in a heparinized microhematocrit capillary tube (Scientific Products, McGaw 
Park, IL). Assessments of systemic hematocrit were performed at control conditions and 
after hemodilution Steps 1 and 2. 
The target value of HF after each hemodilution step was defined by the following 
equation: 
Equation 7 
where VHD is the hemodilution volume. This volume of blood is withdrawn and replaced 
with an equal volume of hemodiluent. Therefore, the volume of blood that needs to be 
removed and then replaced is: 
Equation 8 
PO2 measurements were made during control conditions (N = 16) and after 
hemodilution Step 2 in ten animals, five for each Hespan and Oxyglobin conditions. PO2 
measurements were also made after the intermediate hemodilution Step 1, eight for each 
Hespan and Oxyglobin conditions. 
Statistics 
Data within these experiments are shown as mean h standard deviation in tables 
and mean * error in figures. One Way Analysis of Variance (ANOVA) was conducted 
with the software JMP version 4 (SAS Institute Inc., Cary NC) to assess statistical 
significance for the means of each experimental condition. Statistical significance 
between PO2 values in the different hemodilution steps was determined using Tukey's 
Multiple Comparison test. Additional testing of APO2 values in the different 
hemodilution steps was accomplished with a Student's t-test. Linear regression statistics 
were also calculated using JMP version 4. Statistical significance was taken to be p < 
0.05. 
RESULTS 
Phosphorescence Amplitude, Light Transmission and PO2 
An example of simultaneous one second recordings containing 100 consecutive 
points for measurements of PO2, PA, and LT are shown in Figure 3 for a single capillary 
after Step 1 of isovolemic hemodilution with Hespan. The PA and LT signals changed in 
parallel while there were inverse temporal variations of PO2 that occurred in comparison 
to the PA and LT signals. This is demonstrated quantitatively in Figure 4 and Figure 5 
which yielded the following correlation coefficients: 0.905 for PA versus LT, -0.354 for 
PO2 versus LT, and -0.244 for PO2 versus PA. Similar PA and LT modulations were 
observed in other capillaries (n = 10 1). In capillaries where all PO2 measurements (1 00 
data points generating 100 distinct PO2 measurements) were analyzed (n = 5), similar 
modulations in comparison to the single time course presented in Figure 3 were also 
observed. 
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Figure 3. Example of P02, light transmission, and phosphorescence amplitude 
versus time. 
Tracings represented by the non-smoothed lines represent simultaneous one second 
recordings containing 100 consecutive data points taken from a stationary observation 
point in a capillary. Smoothed line represents the data using a 50-20 Hz fast Fourier 
transform (FFT). See text for further explanation. 
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Figure 4. Plot of phosphorescence amplitude versus light transmission. 
PA and LT data are from a simultaneous one second recording containing 100 
consecutive data points taken from a stationary observation point in a capillary and 
plotted here against each other. See text for further explanation. 
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Figure 5. Plots of partial pressure of oxygen versus phosphorescence amplitude and 
light transmission. 
Effects of Hemodilution with Hespan and Oxyglobin on Systemic 
Variables 
Mean Arterial Pressure and Hematocrit 
Systemic hematocrit was reduced in two steps to 26.3 h 2.5 % (Step 1) and then to 
14.6 * 2.3 % (Step 2) through isovolemic hemodilution with Hespan. In a separate group 
of animals, systemic hematocrit was reduced to 28.6 * 2.6 % (Step 1) and then to 12.3 * 
1.1 % (Step 2) through isovolemic hemodilution with Oxyglobin. A Control value of 
39.5 * 2.7 % was used for comparisons with both Hespan and Oxyglobin groups. As 
hematocrit was reduced using Oxyglobin as the hemodilution fluid, the mean arterial 
pressure increased from 102.9 * 10.2 mmHg (Control) to 124.4 * 21.5 mmHg (Step 1) 
and even further to 135.8 h 17.7 mmHg (Step 2). Mean arterial pressure increased when 
Hespan was used as the hemodilution fluid from 102.9 * 10.2 mmHg (Control) to 105.1 h 
16.9 mmHg (Step 1) and decreased after Step 2 to 97.4 * 15.6 mmHg. The values for 
systemic hematocrit and mean arterial pressure for Control, Step 1, and Step 2 for both 
Hespan and Oxyglobin are presented in Table 2 and in graphic form in Figure 6. 
One Way Analysis of Variance yielded statistically significant differences 
between Control, Step 1, and Step 2. Tukey's Multiple Comparisons test revealed 
significant differences with mean arterial pressure values between Control and Steps 1 
and 2 in the Oxyglobin group. Tukey's test also revealed significant differences of 
Oxyglobin Step 2 to both Hespan Steps 1 and 2, while Step 1 of hemodilution with 
Oxyglobin was significant to Hespan Step 1. 
Table 2. Mean (k standard deviation) systemic data for all animals. 
Oxyglobin Hespan HD2 Oxyglobin 
MAP = Mean arterial pressure (mmHg); PaOz = Systemic arterial partial pressure of 
oxygen (mmHg); S,Oz = Arterial oxygen saturation (%); P&02 = Systemic arterial 
partial pressure of carbon dioxide (mmHg); pHa = Systemic arterial pH; [Hb] = Total 
hemoglobin concentration (gldl); Hct = Systemic hematocrit (%); MCHC = Mean 
corpuscular hemoglobin concentration (gldl); [HbIRsc = Red blood cell hemoglobin 
concentration (gldl); [Hb],l,,, = Plasma hemoglobin concentration (gldl); HD 1 = 
Hemodilution Step 1; HD2 = Hemodilution Step 2; N = Number of animals. 
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Figure 6. Plot of mean arterial pressure versus hematocrit for hemodilution with 
Hespan and Oxyglobin. 
The filled circle represents the Control value, the filled and open triangles represent the 
HBOC Oxyglobin values at Step 1 (HB1) and Step 2 (HB2), respectively, and the filled 
and open squares represent Hespan values at Step 1 (HS1) and Step 2 (HS2), 
respectively. Standard error bars are shown. 
* = Significantly different from Control (p<0.05) 
# = Significantly different from both Hespan Steps 1 and 2 (p<0.05) 
1- = Significantly different from Hespan Step 2 ( ~ ~ 0 . 0 5 )  
Mean Arterial Pressure and Plasma Hemoglobin 
The plasma hemoglobin concentration increased from an assumed value of 0 gldl 
(Control) to 3.7 5 1.7 gldl in Step 1 and then to 8.0 h 0.4 gldl in Step 2 for hemodilution 
with Oxyglobin. As plasma hemoglobin concentration incrqased, the mean arterial 
pressure increased from 102.9 * 10.2 mmHg (Control) to 124.4 % 21.5 mmHg after Step1 
and then to 135.8 5 17.7 mmHg after Step 2 of the isovolemic hemodilution procedure 
with Oxyglobin. Step 1 and Step 2 for Hespan are not shown because Hespan makes no 
contribution to plasma hemoglobin concentrations. Linear regression statistics revealed a 
correlation of 0.662 and p value of < 0.0001. These results are presented in Table 3 and 
summarized in graphic form in Figure 7. 
Effects of Hemodilution with Hespan and Oxyglobin on PO2 in 
Capillaries 
Red Blood Cell PO2 and Comparisons with Hematocrit, Total Hemoglobin 
Concentration, and Plasma Hemoglobin Concentration 
Results for the subset of data in which PO2 was measured in capillaries are contained in 
Table 3 and Table 4. 
Red Blood Cell PO2 and Hematocrit 
Red blood cell PO2 decreased from 54.9 5 14.6 mmHg (Control) to 36.7 =t 18.4 
mmHg (Step 1) then to 22.2 5 2.5 mmHg (Step 2) as the hematocrit was reduced from 
38.8 * 1.9 % (Control) to 23.8 h 2.5 % (Step 1) then to 14.6 5 2.3 % (Step 2) through 
isovolemic hemodilution with Hespan. Hemodilution with Oxyglobin exhibited 
Table 3. Mean (h standard deviation) systemic data for animal sub-group. 
1 Hct 
oxyglobin QT I Hespan HDZ roxyglobin JIDZ 
MAP = Mean arterial pressure (mmHg); Pa02 = Systemic arterial partial pressure of oxygen (mmHg); SaOz = Arterial oxygen 
saturation (%); PaC02 = Systemic arterial partial pressure of carbon dioxide (mmHg); pHa = Systemic arterial pH; [Hb] = 
Total hemoglobin concentration (gldl); Hct = Experimental animal systemic hematocrit (%); MCHC = Mean corpuscular 
hemoglobin concentration (gldl); [HbIRBC = Red blood cell hemoglobin concentration (gldl); [Hb],la,,a = Plasma hemoglobin 
concentration (gldl); N = Number of animals; n = Number of capillaries; HD1 = Hemodilution Step 1; HD2 = Hemodilution 
Step 2. 
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Figure 7. Plot of plasma hemoglobin concentration versus mean arterial pressure 
for hemodilution with Oxyglobin. 
HB1 = HBOC Oxyglobin Step 1, HB2 = HBOC Oxyglobin Step 2. Standard error bars 
are shown. 
Table 4. Mean (* standard deviation) partial pressure of oxygen data for animal sub-group. 
Hespan HD1 
(N=2) 
26 
Oxyglobin HD1 
(N=2) 
2 6 
Control 
(N=4) 
46 
Hespan HD2 Oxyglobin HD2 
(N=5) 
5 0 
RBC PO2 
N = Number of animals; n = Number of capillaries; HD1 = Hemodilution Step 1; HD2 = Hemodilution Step 2; PG PO2 = 
Plasma gap partial pressure of oxygen; RBC PO2 = Red blood cell partial pressure of oxygen; AP02 = Difference between 
RBC PO2 and PG PO2; P,02 = Mean capillary PO2. 
$ = Significantly different from Control (p<O.O5) 
* = Significantly different from zero (p<0.05) 
** = Significantly different from zero (p<0.0001) 
a decrease in red blood cell PO2 from 54.9 k 14.6 mmHg (Control) to 34.4 k 10.1 mmHg 
(Step 1) then to 11.6 k 11 .O mmHg (Step 2) as the hematocrit was reduced from 38.8 k 
1.9 % (Control) to 28.1 k 1.5 % (Step 1) and then to 12.3 k 1.1 % (Step 2). A graphic 
presentation of these data is found in Figure 8. 
A Bivariate Linear Fit Model with subsequent Analysis of Variance revealed a 
statistically significant difference between the linear regressions of Hespan and 
Oxyglobin for red blood cell PO2 versus hematocrit. 
Red Blood Cell PO2 and Total Hemoglobin Concentration 
Red blood cell PO2 decreased from 54.9 k 14.6 mmHg at a total hemoglobin 
concentration of 13.5 k 0.6 gldl to 36.7 k 18.4 mmHg at a total hemoglobin concentration 
of 10.8 k 4.7 gldl after Step 1, and then to 22.2 * 10.6 mmHg at a total hemoglobin 
concentration of 5.1 k 0.8 gldl after Step 2 of Hespan hemodilution. Red blood cell PO2 
sustained a steeper decline when using Oxyglobin as the hemodilution fluid beginning 
with the same Control values as stated previously to a PO2 of 34.4 k 10.1 mmHg at a total 
hemoglobin concentration of 13.1 k 0.4 gldl after Step 1 and then to a PO2 of 11.6 k 11 .O 
mmHg at a total hemoglobin concentration of 1 1.3 k 0.5 gldl after Step 2. A graphic 
presentation of these data is found in Figure 9. 
Hewan 
RBC PO, = 1.33*Hct + 3.57 
R = 0.997 
P = 0.0496 
Oxvelobin 
RBC PO, = 1.62*Hct + -9.19 
R = 0.997 
Hct (%) 
Figure 8. Plot of red blood cell partial pressure of oxygen versus hematocrit for 
hemodilution with Hespan and Oxyglobin. 
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. Linear regression lines are 
shown for Hespan and Oxyglobin as hematocrit was reduced. 
Figure 9. Plots of red blood cell partial pressure of oxygen versus total hemoglobin 
for Hespan and Oxyglobin. 
Conhol 
55 
50 - 
45 - 
- 40  - 
- $ 30- 
20 
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. 
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Red Blood Cell POz and Plasma Hemoglobin Concentration 
Figure 10A graphically presents red blood cell PO2 at a plasma hemoglobin 
concentration of 0 gldl for Control and hemodilution Steps 1 and 2 for Hespan. During 
isovolemic hemodilution with Hespan, the red blood cell PO2 decreased from 54.9 * 14.6 
mmHg (Control) to 36.7 * 18.4 mmHg (Stepl) and then to 22.2 * 10.6 mmHg after Step 
2. Figure 10B depicts the decrease of red blood cell PO2 with increasing plasma 
hemoglobin concentration for hemodilution with Oxyglobin. In this case, red blood cell 
PO2 decreases from 54.9 * 14.6 mmHg (Control) to 34.4 * 10.1 mmHg (Step 1) and then 
to 1 1.6 * 1 1 .O mmHg (Step 2). 
Plasma Gap PO2 and Comparisons with Hematocrit, Total Hemoglobin 
Concentration, and Plasma Hemoglobin Concentration 
Plasma Gap POz and Hematocrit 
With a decrease in hematocrit from 38.3 1.9 % (Control) to 23.8 * 2.5 % (Step 
1) and then to 14.6 * 2.3 % after Step 2 of Hespan hemodilution, the plasma gap PO2 
decreased from 45.1 * 12.9 mmHg (Control) to 35.2 h 18.0 mmHg (Step 1) and then to 
20.9 * 10.3 mmHg (Step 2). Oxyglobin plasma gap PO2 values decreased to 32.8 h 10.0 
mmHg with a hematocrit of 28.1 * 1.5 % after Step 1 to a plasma gap PO2 of 1 1.6 * 1 1.0 
mmHg and hematocrit of 12.3 * 1.1 % after Step 2. Hematocrit can be found in Table 3 
(p. 42) and plasma gap PO2 can be found in Table 4 (p. 44). These data are also 
presented in graphic form in Figure 1 1. 
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Figure 10. Plots of red blood cell partial pressure of oxygen versus plasma 
hemoglobin for Hespan and Oxyglobin. 
HSl = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. 
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Figure 11. Plot of plasma gap partial pressure of oxygen versus hematocrit for 
hernodilution with Hespan and Oxyglobin. 
HSl = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. Linear regression lines are 
shown for Hespan and Oxyglobin as hematocrit was reduced. 
A Bivariate Linear Fit Model with subsequent Analysis of Variance revealed a 
statistically significant difference between the linear regressions of Hespan and 
Oxyglobin for plasma gap PO2 versus hematocrit. 
Plasma Gap PO2 and Total Hemoglobin Concenttation 
As the total hemoglobin concentration decreased from 13.5 + 0.6 gldl (Control) to 
10.8 + 4.7 gldl (Stepl) and then to 5.1 * 0.8 gldl (Step 2), the plasma gap PO2 decreased 
from 45.1 * 12.9 mmHg (Control) to 35.2 * 18.0 mmHg (Step 1) and then to 20.9 f 10.3 
mmHg (Step 2) when using Hespan as the hemodilution fluid. In the case of Oxyglobin, 
there was a decrease in plasma gap PO2 from 45.1 k 12.9 mmHg (Control) to 32.8 10.0 
mmHg (Stepl) and then to 11.6 f 1.2 mmHg after Step 2 hemodilution over a change in 
total hemoglobin concentration from 13.5 k 0.6 gldl (Control) to 13.1 f 0.4 gldl (Step 1) 
and then to 11.3 k 0.5 gldl (Step 2). Total hemoglobin concentrations can be found in 
Table 3 (p. 42) and plasma gap PO2 can be found in Table 4 (p. 44). These data are also 
presented in graphic form in Figure 12. 
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Figure 12. plots of plasma gap partial pressure of oxygen versus total hemoglobin 
for Hespan and Oxyglobin. 
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HBl = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. 
Plasma Gap POz and Plasma Hemoglobin Concentration 
Control plasma gap PO2 was 45.1 k 12.9 mmHg at an assumed plasma 
hemoglobin concentration of 0 gldl. Plasma gap PO2 for Hespan Steps 1 and 2 decreased 
from Control to 35.2 h 18.0 mmHg and 20.9 i 10.3 mmHg, respectively, also at plasma 
hemoglobin concentrations of 0 gldl. Using Oxyglobin as the hemodilution fluid, plasma 
hemoglobin concentrations increased from 5.3 i 1.5 gldl (Step 1) to 8.0 h 0.4 gldl (Step 
2) and plasma gap PO2 decreased to 32.8 i 10.0 mmHg (Step 1) and then to 11.6 i 1.2 
mmHg (Step 2). Plasma hemoglobin concentrations can be found in Table 3 (p. 42) and 
plasma gap PO2 can be found in Table 4 (p. 44). A graphic representation of these data is 
found in Figure 13. 
Red Blood Cell - Plasma Gap PO2 Difference (APOJ and Comparisons with 
Hematocrit, Total Hemoglobin Concentration, Plasma Hemoglobin 
Concentration, and Red Blood Cell PO2 
APOz and Hematocrit 
Using Hespan as the hemodilution fluid, hematocrit decreased from 38.8 h 1.9 % 
(Control) to 23.8 k 2.5 % (Step 1) and then to 14.6 i 2.3 % (Step 2) while AP02 
decreased from 9.7 i 9.1 mmHg (Control) to 6.2 k 9.2 mmHg (Step 1) and then to 1.3 i 
2.0 mmHg (Step 2). Using Oxyglobin as the hemodilution fluid, hematocrit decreased 
from 28.1 h 1.5 % (Step 1) to 12.3 i 1.1 % (Step 2), while AP02 decreased to 1.6 i 2.6 
mmHg (Step 1) and then to 0.0 i 1.1 mmHg (Step 2) from 9.7 k 9.1 mmHg (Control). 
Hematocrit can be found in Table 3 (p. 42) and AP02 can be found in Table 4 (p. 44). 
These data are also presented in graphic form in Figure 14. 
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Figure 13. Plots of plasma partial pressure of oxygen versus plasma hemoglobin for 
Hespan and Oxyglobin. 
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. 
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Figure 14. APOz versus hematocrit. 
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. 
AP02 and Total Hemoglobin Concentration 
The total hemoglobin concentration was decreased during isovolemic 
hemodilution with Hespan from 13.5 h 0.6 gldl (Control) to 10.8 * 4.7 gldl (Step 1) and 
then to 5.1 * 0.8 gldl (Step 2). During this time the AP02 decreased from 9.7 k 9.1 
mmHg (Control) to 1.6 * 5.4 mmHg (Step 1) and then to 1.3 * 2.0 mmHg (Step 2). The 
total hemoglobin concentration decreased during isovolemic hemodilution with 
Oxyglobin from 13.5 * 0.6 gldl (Control) to 13.1 0.4 gldl (Step 1) and then to 11.3 f 
0.5 gldl (Step 2). The AP02 decreased from 9.7 h 9.1 mmHg (Control) to 1.6 h 2.6 
mmHg (Step 1) and then to 0.0 f 0.8 mmHg (Step 2) using Oxyglobin as the 
hemodilution fluid. Total hemoglobin concentration can be found in Table 3 (p. 42) and 
A PO2 can be found in Table 4 (p. 44). These data are also presented in graphic form in 
Figure 15. 
AP02 and Plasma Hemoglobin Concentration 
AP02 decreased from 9.7 h 9.1 mmHg (Control) at a plasma hemoglobin 
concentration of 0 gldl to 1.6 f 5.4 mmHg (Step 1) and then to 1.3 f 2.0 mmHg (Step 2) 
with corresponding plasma hemoglobin concentrations of 0 gldl (Steps 1 and 2) for 
Hespan isovolemic hemodilution. For Oxyglobin, APO2 decreased to 1.6 f 2.6 mmHg 
(Step 1) and then to 0.0 f 1.1 mmHg (Step 2) from Control with corresponding plasma 
hemoglobin concentrations of 5.3 f 1.5 gldl (Step 1) and 8.0 f 0.4 gldl (Step 2). Plasma 
hemoglobin concentration can be found in Table 3 (p. 42) and AP02 can be found in 
Table 4 (p. 44). These data are also presented in graphic form in Figure 16. 
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Figure 15. APOz versus total hemoglobin concentration. 
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are show 
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Figure 16. AP02 versus plasma hemoglobin concentration. 
HS1 = Hespan Step 1, HS2 = Hespan Step 2, HB1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. 
AP02 and Red Blood Cell POz 
Red blood cell PO2 and AP02 were highest at the Control values of 54.9 h 14.6 
mmHg and 9.7 h 9.1 mmHg, respectively. Red blood cell PO2 and AP02 decreased to 
36.7 h 18.4 mmHg and 1.6 * 5.4 mmHg, respectively, after Step 1 of Hespan 
hemodilution. Red blood cell PO2 and AP02 decreased to 22.2 h 10.6 mmHg and 1.3 * 
2.0 mmHg, respectively, after Step 2 of Hespan hemodilution. With Oxyglobin as the 
hemodilution fluid, red blood cell PO2 and AP02 decreased from Control to 34.4 * 10.1 
mmHg and 1.6 * 2.6 mmHg, respectively, after Step 1 and then to a red blood cell PO2 of 
11.6 h 1 1.0 mmHg and APOz of 0.0 * 1.1 mmHg after Step 2. Red blood cell PO2 and 
AP02 can be found in Table 4 (p. 44). These data are also presented in graphic form in 
Figure 17. 
Results of Statistical Analysis 
A One Way Analysis of Variance revealed that all values for Hespan and 
Oxyglobin for both Steps 1 and 2 were significantly different from Control for plasma 
gap PO2 and red blood cell PO2 with all p-values less than 0.05. In addition, for both 
plasma gap PO2 and red blood cell PO2, Tukey's Multiple Comparisons test revealed 
significant differences between all values except among Hespan and Oxyglobin Step 1. 
Students t-tests determined significant differences between plasma gap PO2 and red blood 
cell PO2 (AP02) in the Control group (p<0.0001), hemodilution Step 1 with Oxyglobin 
(p<0.05), and hemodilution Step 2 with Hespan (p<0.000 1). 
Figure 17. A P 0 2  versus red blood cell partial pressure of oxygen. 
HS 1 = Hespan Step 1, HS2 = Hespan Step 2, HB 1 = HBOC Oxyglobin Step 1, HB2 = 
HBOC Oxyglobin Step 2. Standard error bars are shown. 
DISCUSSION 
Theoretical models have predicted the existence of intracapillary PO2 gradients 
that take into account the discrete nature of blood flow in capillaries. Hellums was the 
first to do so in 1977 (Hellums 1977). The first experimental evidence to support these 
predictions determined that plasma POz gradients do exist in the form of erythrocyte- 
associated transients or EATs (Golub and Pittman 2005). The purpose of the present 
study was to observe EATs in skeletal muscle capillaries. Furthermore, the purpose 
extended towards describing the nature of EATs under isovolemic hemodilution 
conditions with Hespan and a hemoglobin-based oxygen carrier. By employing the Pd- 
porphyrin phosphorescence quenching method (PQM) along with measuring light 
transmission, it was possible to determine the relative presence or absence of red blood 
cells in the detection volume over a one second time course. 
There were three major findings from this study and multiple minor findings that 
will be discussed in this section. The first major finding is that EATs can be measured in 
skeletal muscle using prior detection methods as were applied to the rat mesentery 
(Golub and Pittman 2005). Secondly, the magnitude of EATs depends on capillary POz 
values. Thirdly, the magnitude of EATs is dependent on hematocrit and plasma 
hemoglobin concentration and that these values vary depending on the hemodilution fluid 
used. 
Prior Documentation on Erythrocyte-Associated Transients, 
Hemodilution and Hemoglobin-Based Oxygen Carriers 
The present study is unique for several reasons. Although the description of 
intracapillary PO2 heterogeneity (Hellums 1977; Homer, Weathersby et al. 198 1) allowed 
a framework for mathematical modeling which predicted the presence of PO2 gradients 
between M C s  and plasma (Federspiel and Sarelius 1984; Federspiel and Pope1 1986; 
Hellums, Nair et al. 1996), Golub and Pittman (2005) collected the first experimental data 
from capillaries in the rat mesentery, demonstrating the existence of EATS. The present 
investigation used the rat spinotrapezius muscle and made measurements under 
hemodilution conditions with two hemodiluents for the first time. 
Phosphorescence Amplitude and Light Transmission 
Laser excitation of the Pd-porphyrin phosphorescent probe confined to the plasma 
allowed the measurement of plasma PO2 transients and the determination of 
phosphorescence amplitude (PA). The discrete nature of blood flow was also revealed by 
the simultaneous measurement of light transmission (LT) through the capillary. As a 
result of the intrinsic nature of red blood cells (RBC) to absorb light, the signal would 
decrease in the presence of a IU3C and increase once the RBC moved out of the detection 
region. The signal for PA would correspondingly increase, reflecting the presence of 
plasma measured by the amount of light emitted by the excited phosphor probe in the 
detection region, and decrease when an IU3C was present (i.e., less plasma). 
Ideally, PA and LT amplitude fluctuations would correspond exactly. Although 
these two independent variables were sometimes highly correlated, this was not always 
the case. Golub and Pittman (2005) found that, due to the complex refraction of 
transmitted light by a RBC with random size, shape, and orientation and possible 
misalignment of the photodiode used to measure LT under the tissue, PA was a better 
indicator of the presence of plasma or RBCs. Other factors that might contribute to 
variability between these two factors in skeletal muscle are muscle thickness, refraction 
of transmitted light by muscle tissue, and the presence of multiple microvessels along the 
incident light beam. 
The expectation for the isovolemic hemodilution protocol with Hespan was that 
LT and PA signal tracings would be more pronounced with troughs and peaks becoming 
more widely spaced. The expectation for the isovolemic hemodilution protocol with 
Oxyglobin was that PA signal tracings would show a decreased distinction between 
troughs and peaks, resulting from the increased plasma hemoglobin concentration. 
Neither of these expectations was observed in reviewing LT and PA signal 
tracings from Control and Steps 1 and 2 for hemodilution with either Hespan or 
Oxyglobin. In fact, the relative spacing of plasma gaps and RBCs remained relatively 
unchanged from Control to hemodilution conditions. This could be explained in part by 
the observation of capillary networks during experimentation where RBCs did not appear 
to be distributed uniformly in all capillaries; rather, some capillary networks became 
plasmatic while other capillaries maintained a relatively normal RBC flow. 
It is also interesting to note that in multiple capillaries the PA signal population 
appeared to be bimodal. One possible explanation for this is that the two separate 
populations represent values corresponding to RBCs and plasma gaps (Figure 18). This 
explanation corresponds to previously presented ideas that the LT and PA signals should 
be higher when the detection volume is comprised of plasma and lower when a RBC is 
present. 
Effects of Hemodilution on Systemic Parameters 
Summary of Experimental Results for Mean Arterial Pressure and Hematocrit 
Hemodilution with Hespan resulted in an overall decrease in mean arterial 
pressure as the hematocrit was reduced. For Hespan, mean arterial pressure went from 
102.9 * 10.2 mmHg (Control) to 105.1 * 16.9 mmHg (Step 1) and decreased after Step 2 
to 97.4 * 15.6 mmHg. In the case of hemodilution with Oxyglobin, a progressive 
increase in mean arterial pressure occurred as the hematocrit was reduced. For 
Oxyglobin, mean arterial pressure went from 102.9 + 10.2 mmHg (Control) to 124.4 * 
21.5 mmHg (Step 1) and even further to 135.8 * 17.7 mmHg (Step 2). The infusion of 
Oxyglobin caused an immediate and statistically significant increase in mean arterial 
pressure following hemodilution Step 1. After Step 2 hemodilution there was a sustained 
increase in mean arterial pressure, yet the difference between MAP for Step 1 and Step 2 
was no longer significant. The means for both Oxyglobin Steps 1 and 2 were 
significantly different from the MAP for Hespan Step 2. 

Explanation of Variation in Results 
In several of the Hespan experiments leading to Step 1 measurements and in 
several of the Oxyglobin experiments leading to Step 2 measurements, technical 
difficulties regarding the wi thdrawallinfusion protocol caused an overshoot in 
hemodilution. In both animals of the Hespan Step 2 group, hematocrit was substantially 
lower than the target hematocrit of 30% (22% and 25%) and, in three of five animals for 
the Oxyglobin Step 2 group, hematocrit was lower than the target hematocrit of 15% 
(1 I%, 12%, and 12%). There was also an unexplained rise in mean arterial pressure for 
hemodilution Step 1 using Hespan as the hemodilution fluid (see Figure 6, p. 40). 
Summary of Experimental Results for Mean Arterial Pressure and Plasma 
Hemoglobin Concentration 
Isovolemic hemodilution with Oxyglobin caused an increase in plasma 
hemoglobin concentration as expected from the assumed value of 0 gldl (Control) to 3.7 - 
h 1.7 gldl in Step 1 and then to 8.0 * 0.4 gldl in Step 2. The results demonstrate that a 
rise in free hemoglobin concentration correlated well with a rise in mean arterial pressure. 
Results and Comparisons in Prior Investigations for Mean Arterial Pressure 
The mean arterial pressure obtained through hemodilution with Hespan and 
Oxyglobin are consistent with the results of previous studies. A number of studies have 
described a decrease in mean arterial pressure during isovolemic hemodilution with a 
non-oxygen-carrying plasma expander, apparently due to the consequential decrease in 
blood viscosity (Krieter, Hagen et al. 1997; Tsai, Friesenecker et al. 1998; Tsai and 
Intaglietta 2001). The pressor effect of hemoglobin-based oxygen carriers is also well 
documented. There are primarily two competing theories as to the mechanism of the 
hypertensive effect of HBOCs, either that nitric oxide (NO) scavenging occurs in the 
vessel lumen andlor in the extravascular space or that there is excessive 0 2  delivery. The 
former is the most widely accepted interpretation. Several studies describe in detail the 
mechanism by which extracellular oxy-hemoglobin (Hb02) reacts at a high rate with NO 
in the vessel lumen. Extravasation of Hb02 into the blood vessel wall also causes a 
reaction to occur with NO in the extravascular space, thereby hampering normal NO 
signaling that occurs between the endothelium and the smooth muscle (Shen, Hintze et al. 
1995; Sarti, Giuffre et al. 2003; Olson, Foley et al. 2004). 
Effects of Hemodilution with Hespan and Oxyglobin on Capillary PO2 
Summary of Experimental Results for Red Blood Cell PO2 
Hemodilution with Hespan resulted in a linear decrease in RBC PO2 as the 
hematocrit was systematically decreased through the two hemodilution steps (see Figure 
17). Hemodilution with Oxyglobin caused a similar linear decrease in RBC PO2. A 
statistically significant difference was found when comparing the two linear regressions 
using a Bivariate Linear Fit Model with subsequent Analysis of Variance indicating that 
Hespan over the entire course of hemodilution was able to maintain RBC PO2 better than 
Oxyglobin. The linearity of both Hespan and Oxyglobin data suggest that RBC PO2 is 
dependent on hematocrit. 
Hemodilution with Hespan resulted in the expected decrease in total hemoglobin 
concentration and concurrent decrease in RBC PO2 to 22.2 * 10.6 mmHg. Using 
Oxyglobin as the hemodiluent the total hemoglobin concentration was kept above 11 
gldl, but the RBC PO2 sustained a much steeper decline with a POz of 1 1.6 * 1 1.0 mmHg 
in Step 2. 
Plasma hemoglobin concentrations increased from 5.2 * 1.5 gldl (Step 1) and then 
to 8.0 * 0.4 gldl as expected, contributing significantly to the total hemoglobin 
concentrations of 13.1 k 0.4 gldl (Step 1) and 11.3 * 0.5 gldl (Step 2). RBC PO2, despite 
the contribution of free hemoglobin to the plasma, did not benefit from its increased 
oxygen carrying capacity. 
RBC PO2 decreases in capillaries amid the decrease in systemic hematocrit and 
hemoglobin concentrations because there are fewer red blood cells to deliver oxygen and 
maintain tissue consumption levels. Therefore, more oxygen off loading occurs in 
arterioles before the red blood cells reach the capillaries resulting in the low RBC P02. 
This process might be facilitated by the addition of cell-free hemoglobin. 
Overall, all RBC PO2 values for the hemodilution Steps 1 and 2 for Oxyglobin 
and Hespan were determined to be statistically significant from Control values using a 
One Way Analysis of Variance. Tukey's Multiple Comparisons test revealed that all 
other values are significant when compared to each other except Step 1 values. 
Summary of Experimental Results for Plasma Gap PO2 
Hemodilution with Hespan resulted in a linear decrease in PG PO2 as hematocrit 
was systematically decreased through the hemodilution steps. Hemodilution with 
Oxyglobin caused a similar linear decrease in PG PO2. Although the linear correlation 
for the Hespan values is 0.971 it is not statistically significant (p = 0.15). Linear 
regression statistics indicate a similarly high linear correlation for Control and Oxyglobin 
Steps 1 and 2 (R = 0.999) that is statistically significant (p = 0.027). When comparing 
the linear regressions using a Bivariate Linear Fit Model with subsequent Analysis of 
Variance, a significant difference was revealed indicating that Hespan, over the entire 
course of hemodilution, yielded a higher PG POz than Oxyglobin. The high linear 
correlation of both Hespan and Oxyglobin data indicates that most of the variation of PG 
PO2 can be accounted for the hematocrit. 
PG PO2 versus total hemoglobin concentration and plasma hemoglobin closely 
parallel those of the RBC PO2 plots. One note of interest is that PG PO2 was 32.8 * 10.0 
mmHg (Step 1) and 1 1.6 * 1 1.0 mmHg (Step 2) when using Oxyglobin as the 
hemodiluent. Using Hespan as the hemodiluent resulted in PG PO2 values of 35.2 * 18.0 
mmHg (Step 1) and 20.9 * 10.3 mmHg (Step 2). 
One Way Analysis of Variance determined that the PG PO2 values of 
hemodilution Steps 1 and 2 for Oxyglobin and Hespan are statistically significant 
compared to Control values. Tukey's Multiple Comparisons test revealed that the Step 1 
values for Oxyglobin and Hespan are not significantly different, while there is a 
significant difference between Oxyglobin Step 2 and Hespan Step 2. PG PO2 was 
expected to be higher for the Oxyglobin groups considering the contribution of cell-free 
hemoglobin in the plasma. 
Summary of Experimental Results for APOz 
As hematocrit was systematically reduced during hemodilution using Hespan and 
Oxyglobin, AP02 was dramatically reduced after Step 1. APO2 for Steps 1 and 2 of the 
hemodilution protocol with Hespan were approximately the same (1.6 i 5.4 mmHg and 
1.3 f 2.0 mmHg, respectively), while AP02 for Steps 1 and 2 using Oxyglobin as the 
hemodiluent varied slightly (1.6 i 2.6 mmHg and 0.0 * 1.1 mmHg, respectively). 
When considering the dependence of AP02 on total hemoglobin concentration, 
there was approximately an 8 mmHg change in APOz going from a total hemoglobin 
concentration of 13.5 i 0.6 gldl (Control) to 10.8 f 4.7 gldl (Step I), when using Hespan 
as the hemodiluent. This was only a small and non-significant change in AP02 between 
hemodilution Steps 1 and 2 using Hespan. Using Oxyglobin as the hemodilution fluid, 
total hemoglobin concentration varied only slightly, decreasing from 13.5 * 0.6 gldl 
(Control) to 1 1.3 f 0.5 gldl (Step 2), and AP02 decreased to 0.0 * 1.1 mmHg. 
Consideration of the plasma hemoglobin concentration provides additional insight 
into the variation of AP02 with total hemoglobin concentration. Hemodilution with 
Oxyglobin adds extracellular hemoglobin molecules which causes total hemoglobin 
concentration to remain stable during hemodilution. As more cell-free hemoglobin was 
added to the plasma from 0 gldl (Control) to 5.3 i 1.5 gldl (Step 1) and then to 8.0 * 0.4 
gldl (Step 2), the difference in POz between RBCs and plasma gaps virtually disappeared, 
as expected. 
Student's t-tests determined that significant differences exist between plasma gap 
PO2 and red blood cell POz (AP02) in the following: 1) Control group (p<0.0001) with a 
AP02 of 9.7 k 9.1 mmHg; 2) Oxyglobin hemodilution Step 1 (p<0.05) with a APOz of 1.6 
k 2.6 mmHg; 3) Hespan hemodilution Step 2 (p<0.0001) with a APOz of 1.3 k 2.0 
mmHg. 
Interpretation of Results and Comparison with Prior Investigations 
The components of total hemoglobin concentration of the blood, namely the 
concentration of hemoglobin contained within RBCs and that contained in the plasma 
were calculated from the following equation: 
where [HbITotal is the total hemoglobin concentration in the blood, [HbIRBC is the 
hemoglobin concentration of a single RBC, Hf is the final hematocrit, and [Hb],laSma is the 
hemoglobin concentration in the plasma. 
Hemodilution with Hespan caused almost a three-fold reduction in total 
hemoglobin concentration, dropping below the transfusion trigger for packed red blood 
cells normally recognized at 7 gldl (Intaglietta 1999; Tsai and Intaglietta 2001) after Step 
2 ([Hb]plas,a = 5.1 k 0.8 gldl). This explains the significant decrease in RBC and mean 
capillary POz (Table 4). The addition of extracellular hemoglobin molecules in the form 
of Oxyglobin increased plasma hemoglobin concentration, keeping total hemoglobin 
concentration close to the Control value. Although total hemoglobin concentration was 
stabilized by the addition of cell-free hemoglobin, it did not improve the overall delivery 
of oxygen to the capillaries as evident in the mean capillary PO2. Equalization of PO2 
between the RBCs and plasma gaps was observed after the final hemodilution step with 
Oxyglobin resulting in a AP02 of practically 0 mmHg. Although this result was 
expected, if not so dramatically, Oxyglobin did not have a stabilizing effect on mean 
capillary PO2; rather, it caused a decrease to approximately one-half of the Hespan Step 2 
capillary PO2 value. Prior investigations in our laboratory using measurements taken at 
the arteriolar and venular ends of capillaries to determine capillary PO2 (Miller 2000; Tait 
2000), have shown that capillary PO2 decreases with systematic reduction of hematocrit 
when using Hespan as a hemodiluent. However, when using different HBOCs as the 
hemodiluent, mean capillary PO2 remained at stable levels throughout the systematic 
reduction in hematocrit. This led to the conclusion that total hemoglobin concentration is 
a major determinant of capillary PO2. This is contrary to the results obtained with 
Oxyglobin in this study. 
Although MAP increased and total hemoglobin concentration was well 
maintained with the addition of Oxyglobin, PO2 in the capillaries was dramatically 
reduced. Oxygen-carrying plasma expanders should reduce intracapillary resistance, 
facilitating oxygen offloading into nearby tissue, and should also increase the oxygen 
carrying capacity in the blood maintaining near to normal values as mentioned above. 
Tsai (Tsai 2001) reported abnormally low tissue oxygenation and functional capillary 
density (FCD), a measurement of the number of red blood cell perfused capillaries as a 
measure of oxygen supply, with Oxyglobin during low hemoglobin content conditions 
(<50%). Perhaps this can help to explain the abnormally low mean capillary PO2 
observed in this case. 
Another facet to the explanation of abnormally low mean capillary PO2 that is 
seen with this particular HBOC might be due to NO scavenging. Evidence from multiple 
studies demonstrate that NO reversibly inhibits cytochrome c oxidase, the terminal 
enzyme of the mitochondrial respiratory chain (Brown and Cooper 1994; Cleeter, Cooper 
et al. 1994; Schweizer and Richter 1994; Sarti, Giuffre et al. 2003). In fact, nanomolar 
concentrations of NO cause the inhibition of cytochrome c oxidase which inhibits normal 
mitochondrial function causing oxygen consumption to decrease (Brown and Cooper 
1994). One particular study found that the inhibition of NO synthesis with nitro-L- 
arginine (NLA, lo4 moVL) caused the opposite to occur, consumption of oxygen 
increased in the tissue by 55*9% (Shen, Hintze et al. 1995). 
Putting this into the context of hemodilution with a HBOC, NO scavenging that 
occurs intravascularly in combination with HBOC extravasation into the interstitial space 
between the vascular endothelium and smooth muscle could potentially scavenge enough 
NO to mimic the effects of NLA. Considering this facet of NO activity along with 
reduced FCD and vasoconstriction, capillaries observed in the current study may have 
uniquely experienced a drastic reduction of oxygen supply and a concurrent increase in 
demand resulting in very low mean capillary PO2 at a reduced hematocrit when using 
Oxyglobin as the hemodilution fluid. 
The present study is the first to combine a hemodilution procedure with EAT 
measurements in skeletal muscle. A prior investigation from this laboratory determined 
PO2 in single capillaries, taking into account heterogeneity in PO2, indicating the 
presence of PO2 gradients within the plasma (Zheng, Golub et al. 1996). More recent 
experimental data from this laboratory, using the rat mesentery, concluded the existence 
and measurability of PO2 gradients within the plasma gaps between RBCs (Golub and 
Pittman 2005). The present study has made the determination that the magnitude of the 
EATs depends on the capillary PO2 values. Table 4 shows the general trend of a 
corresponding decrease in capillary PO2 and AP02 for the one second observation period. 
Golub and Pittman (2005) found that EATs in mesenteric capillaries were less prominent 
in capillaries with high average PO2 and more prominent in capillaries with low P02. 
Results from this study found that the largest AP02 with statistical significance occurred 
in the Control group, which had the highest capillary PO2. Other statistically significant 
differences in AP02 were revealed in Oxyglobin Step 1 and Hespan Step 2. Though 
statistically significant, the latter condition was hypothesized to have the largest AP02 
because of an expected increase in spacing between RBCs when hematocrit is reduced 
which in turn increasing intracapillary resistance to oxygen delivery resulting in an 
increase in EAT transients. 
For normal cell separation distance (about 10 pm) and oxygen content of RBCs, 
the magnitudes of EATs in capillaries of resting tissue have predicted values of 10 mmHg 
(Wang and Popel 1993; Kisliakov 1996), consistent with the Control AP02 from this 
investigation. Another study calculated oxygen PO2 gradients in peripheral capillaries 
(Lawson and Forster 1967). Calculating the PO2 difference between red cells and plasma 
under numerous conditions, they hypothesized that under normal resting conditions APOz 
should be 0.2 mmHg and under anemic conditions ([Hb]~otal= 3.7 gldl) AP02 should be 
1.1 mmHg. These calculations were not completely congruent with the data collected in 
this study. Under Control conditions (considered normal resting) AP02 was highest at 
9.7 * 9.1 mmHg and under similar anemic conditions ([HbITot,, = 5.1 * 0.8 gldl, Hespan 
Step 2) AP02 1.3 * 2.0 mmHg. Many other mathematical calculations have predicted a 
much higher AP02 than what has been observed either by this study or by Golub and 
Pittman (Homer, Weathersby et al. 198 1 ; Wang and Pope1 1993; Golub and Pittman 
2005). 
Finally, it was suggested by Golub and Pittman (2005) that intracapillary 
resistance would decrease with the addition of an oxygen-carrying blood substitute, 
thereby damping the modulation of EATS. This is consistent with the present study 
which found no statistical significance in AP02 for hemodilution Step 2 with Oxyglobin, 
where the final hematocrit was one-third what it was initially and total hemoglobin 
deviated only slightly from the Control value. 
Summary and Conclusion 
Hemodilution with Oxyglobin resulted in a significant increase in mean arterial 
pressure as hematocrit was reduced and resulted in a significant contribution to total 
hemoglobin concentration. Conversely, hemodilution with Hespan did not significantly 
alter mean arterial pressure and resulted in a dramatic decrease in total hemoglobin 
concentration, below the transfusion trigger after Step 2. 
Considering EATS, it was determined that the magnitude of EAT modulation 
decreased with decreased capillary PO2. Furthermore, it was determined that the 
magnitude of EAT modulation was related to hematocrit and hemoglobin concentration 
and that these varied depending on the hemodiluent used. With the systematic reduction 
of hematocrit, both hemodiluents caused a rapid decline in RBC and PG PO2. At the 
hemodilution levels used in this study, Hespan demonstrated the ability to maintain PO2 
at higher levels when compared to Oxyglobin. Although Oxyglobin maintained total 
hemoglobin concentration near normal, with a significant contribution to the plasma 
hemoglobin concentration, it did not increase the oxygen delivery of blood in the 
capillaries but did cause EAT modulation to minimize, reducing the PO2 gradient 
between the plasma and red blood cells. Hespan had no effect on hemoglobin 
concentration. 
AP02 was determined to be statistically significant in three of the five 
experimental conditions including Control, Oxyglobin Step 1, and Hespan Step 2. The 
largest numerical AP02 occurred under Control conditions. Furthermore, the addition of 
Oxyglobin increased plasma hemoglobin concentration, keeping total hemoglobin 
concentration well above the "transfusion trigger", while causing the virtual abolishment 
of a PO2 gradient between RBCs and plasma gaps. In conclusion, using PQM and the 
previous experimental parameters of Golub and Pittrnan (2005), EATs in capillary PO2 
have been observed experimentally in the rat spinotrapezius muscle. 
Recommendations for Future Studies 
Parameters used in mathematical models, such as lineal density of RBCs, RBC 
spacing, RBC velocity, and RBC shape (Federspiel and Sarelius 1984; Federspiel and 
Pope1 1986; Groebe and Thews 1989; Tsai and Intaglietta 1989; Wang and Pope1 1993), 
should be experimentally measured to help answer questions concerning inter-RBC PO2 
resistance, oxygen flux at the capillary wall, and tissue PO2 oscillations associated with 
PO2 gradients between red blood cells and plasma gaps. A proposed technique to allow 
the determination of the values mentioned above would be the simultaneous 
measurement of EATs and video images of red blood cells and plasma gaps. With the 
dual acquisition of PO2 and spatial data, the relationship between PO2 and other variables 
such as RBC and capillary geometry and RBC flow dynamics could be compared with 
predictions of mathematical models. 
Measurement of EATs in contracting skeletal muscle, where there is increased 
blood flow (with shorter residence time for RBCs in capillaries) and higher oxygen 
consumption, would be of interest to study the effects of the discrete nature of blood flow 
on oxygen transport to tissue via capillaries. A previous mathematical model (Groebe 
and Thews 1989), considered the impact of increased inter-erythrocyte plasma gap 
spacing and concluded that plasma gap spacing does not play an important role for tissue 
oxygen supply as long as overall capillary oxygen flux stays constant. Perhaps, 
examining EATs under exercise conditions with increased red blood cell flux in 
capillaries and capillary recruitment can shed some light on this and similar issues. The 
effects of Oxyglobin and other hemoglobin-based oxygen carriers on EATs and capillary 
PO2 under these conditions might also be considered. 
Another proposal related to the present study would be the determination of 
functional capillary density following administration of Oxyglobin. Various studies have 
reported conflicting conclusions regarding the ability of hemoglobin-based oxygen 
carriers to maintain or decrease functional capillary density (Tsai, Friesenecker et al. 
1995; Tsai 2001) with one study involving the use of Oxyglobin. Furthermore, FCD 
determination after the administration of an HBOC in conjunction with a vasodilator 
might also be of interest. 
Finally, future study involving the comparison of Oxyglobin to the human HBOC 
product from Biopure would be worthwhile. The human product ~ e m o ~ u r e @ ,  or HBOC- 
201, is a bovine hemoglobin glutamer - 250. As a result of its increased size (32 to 500 
kD compared to Oxyglobin molecular weight between 65 and 130 kD with no more than 
10% having a molecular weight >500 kD) and improved purification, different results 
may be observed. 
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